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SUMMARY AND CONCLUSIONS 
 
 
SUMMARY AND CONCLUSIONS 
 
Infections due to Streptococcus pneumoniae (pneumococcus) annually cause 1 to 2 million 
deaths among children less than 5 years of age. An effective and globally available vaccine 
against pneumococcus could provide a substantial public health and economic impact in both 
developing and industrialised countries. The pneumococcal polysaccharide vaccine is not 
sufficiently effective in protecting young children, elderly and immunocompromised 
individuals against pneumococcal infections. The new conjugated pneumococcal vaccines are 
immunogenic already at early age due to the T-cell dependent immune response, which leads 
to increased production of antibodies, development of immunological memory and maturation 
of the immune response. The first 7-valent pneumococcal conjugate vaccine is already 
licensed, after being shown to prevent a great majority of invasive pneumococcal infections 
and majority acute otitis media episodes  caused by the serotypes included in the vaccine, as 
well as significantly reduce radiologically confirmed pneumonia. However, the vaccine has 
only a limited coverage of serotypes causing serious pneumococcal infections in most 
developing countries.  
 
Studies presented in this thesis evaluated the immunogenicity and safety of a new mixed-
carrier diphtheria toxoid and tetanus protein –conjugated 11-valent pneumococcal vaccine in 
Filipino infants. The results show that the vaccine elicited high concentration of functionally 
active antibodies and it was safe and well-tolerated. A surprising finding was that just one 
vaccine dose administered at 18 weeks of age resulted in similar antibody concentrations at 9 
months of age as the conventional three-dose schedule. This might be due to carrier priming of 
the previous immunisations with tetanus and diphtheria vaccines. Antibody response to the 
vaccine was substantially higher in Filipino infants than in Finnish and Israeli infants. Again, 
this might be a result of the priming effect of tetanus toxoid vaccination given to pregnant 
women in the Philippines, or slightly different vaccination schedules.    
 
The results provided justification for further evaluation of the vaccine. The impact of the 
vaccine in reduction of radiologically proven pneumonia in infants is evaluated in an 
effectiveness study, which started in July 2000 in the Philippines. If proven effective and 
introduced into the immunisation programs, the vaccine could provide a substantial reduction 
in the pneumococcal disease burden. 
INTRODUCTION 
 
 
INTRODUCTION 
 
Streptococcus pneumoniae (pneumococcus) is a leading bacterial cause of infection world-
wide, ranging from common respiratory infections (acute otitis media (AOM), sinusitis), to 
life-threatening infections (bacteremia, meningitis, pneumonia) [257]. It has one of the largest 
public health and economic impacts of any infectious disease agents in both developing and 
industrialised countries. According to WHO statistics, pneumococcal infections annually cause 
1 to 2 million deaths among children less than 5 years of age [222]. Rapidly increasing 
antimicrobial resistance of pneumococci, as well as the HIV–pandemic, further increase the 
urgency of the development of effective means to control pneumococcal infections. 
 
Vaccination appears to provide the best means of prevention against pneumococcal infections. 
The pneumococcal polysaccharide vaccine, which was licensed as 14–valent (i. e. containing 
capsular polysaccharides of 14 different pneumococcal serotypes) in 1977 and as 23-valent 
formulation in 1983, is effective in protecting healthy adults against invasive pneumococcal 
disease. Unfortunately people at greatest risk, i.e. young infants, elderly and 
immunocompromised individuals, are the poorest responders to the vaccine. The new 
conjugated pneumococcal vaccines are immunogenic already at early age due to the T-cell 
dependent immune response, which leads to increased production of antibodies, development 
of immunological memory and maturation of the immune response so that the majority of the 
antibodies are of high avidity.  
 
The first 7-valent pneumococcal conjugate vaccine is already licensed in Australia, Europe, 
North America and most countries in Central and South America [432]. The vaccine prevented 
76%-97% [39, 291] of invasive pneumococcal infections caused by the serotypes included in 
the vaccine. It also prevented 20.5%-24.9% (95% CI 4.4%, 34.0%) of radiologically 
confirmed pneumonia [41, 184] and 57 % (95% CI 44%, 67%) of acute otitis media episodes 
caused by the vaccine serotypes [91]. The vaccine is, however, primarily developed for the 
U.S. and European epidemiological situation, and therefore it has only a limited coverage of 
serotypes causing serious pneumococcal infections in most developing countries. The vaccine 
is also more expensive (40-58 USD / dose) than the costs of all other vaccines in national 
immunisation programmes in many developing countries [432].  
 
INTRODUCTION 
 
This thesis is a part of an international ARIVAC research collaboration aiming at evaluating 
the impact of a new 11-valent pneumococcal conjugate vaccine in prevention of serious 
pneumococcal infections in children, especially in developing countries. The thesis is 
composed of two immunogenicity and safety studies, which evaluated the quantitative and 
qualitative antibody responses as well as safety of the vaccine, when given according to 
different vaccination schedules in Filipino infants. Comparison is also made between the 
immunogenicity of the vaccine in Filipino, Finnish and Israeli infants, in order to understand 
factors affecting the immune responses in populations, which differ in their risk factors for 
pneumococcal carriage and disease. This information could assist in determining the optimal 
timing and number of doses required for protection in different countries planning to introduce 
a new pneumococcal vaccine into their national immunisation schedules.   
 
 
 
REVIEW OF LITERATURE 
 
 
1. Virulence factors of Streptococcus pneumoniae  
 
Streptococcus pneumoniae was first isolated and grown by Sternberg and Pasteur in 1881. The 
encapsulated gram-positive bacteria of 0.5-1.25 µm in diameter was subsequently named 
pneumococcus by Fraenkel in 1886 [415]. The complete genome sequence of an isolate of 
serotype 4 was determined in 1997. The genome consists of 2,160,837 base pairs and 2236 
genes or coding regions, of which 1440 (64%) have been assigned a biological role [402]. The 
surface of the bacteria is constructed of three morphologically different layers: plasma 
membrane, cell wall and capsule. The plasma membrane forms the innermost structure. The 
cell wall consists of teichoic acid and peptidoglycan, which anchors surface proteins and cell 
wall polysaccharides (PS), such as C-polysaccharide (CPS) [417]. The cell wall components, 
primarily CPS and lipoteichoid acid, mediate inflammation and can activate the alternative 
complement pathway [153, 422].  
 
The outermost layer consists of a PS capsule, which varies in thickness for different 
pneumococcal serotypes [387]. The capsule is the primary factor for the virulence of the 
bacteria [10, 210, 417]. It protects pneumococcus from phagocytosis by polymorphonuclear 
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leukocytes by shielding the inner structures of the bacterium from antibodies and by separating 
bound antibodies and complement from receptors on phagocytes [51, 52]. Pneumococci that 
lack the capsule are normally avirulent in normal hosts [416]. Antibodies to the capsular PSs 
are the main element in protection against pneumococcal infections [232, 393].  
 
Differences in the chemical structure of capsular PSs provide the basis for classifying 
pneumococci into serotypes. The standard method for serotyping is so-called quellung 
reaction, in which a bacteria suspension is mixed with antiserum and the following distinct 
capsular microprecipitation reaction is observed under microscope. The original quelling 
method, described by Neufeld in 1902, has been simplified by using 
counterimmunoelectrophoresis, coagglutination or latex agglutination methods in a chessboard 
system, consisting of nine pooled antisera and 46 group- or type-specific antisera, or 12 pooled 
antisera [203, 386]. Two different systems of nomenclature exist for the classification of 
pneumococcal serotypes, namely the Danish and the American system. The Danish system is 
based on cross-reactions between different types so that serologically cross-reactive types are 
assigned to a common serogroup. This system classifies pneumococci into 46 
serotypes/groups, numbered 1-48, with a total of 90 different serotypes [144]. The American 
system numbers different serotypes sequentially according to the order of their discovery.  
 
In addition to the PS capsule and cell wall components, several pneumococcal proteins and 
toxins have an important role in the virulence of the bacteria. The pneumococcal surface 
protein A (PspA), which binds to the cell wall choline, inhibits complement activation and 
thus phagocytosis of pneumococci [272]. It is an important pneumococcal protein vaccine 
candidate [46] as it extrudes from the surface of the capsule, is present in all clinical isolates 
[67] and provides protection against carriege, sepsis and pulmonary infection in animal models 
[47, 48, 244, 435]. PspA is highly heterogeneous, but cross-protection against heterologus 
PspA has been demonstrated in mice [45, 244]. The choline binding protein A (CbpA), also 
called pneumococcal surface protein C (PspC), was the first pneumococcal surface protein 
adhesin described. It is important in human colonisation by pneumococci [339], during the 
process from colonisation to invasion [112], and in penetration of pneumococci across the 
blood-brain barrier [112, 333]. It also protects against carriage [25] and bacteremia [49] in 
mice. The pneumococcal surface adhesin A (PsaA) is a 37-kDa surface protein, which has an 
important role in ATP-binding transport system responsible for the import of manganese and 
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zink [36, 206]. In mouse model/mouse models, the antibodies to PsaA seem to be protective, 
especially against the carriage of pneumococci [46, 398].    
 
Pneumolysin (Ply) is a 52.8 kDa cytoplasmic toxin released by autolysis of the cell. It is able 
to damage a wide range of eukaryotic cells, including bronchial and alveolar epithelial cells, 
by rupturing the target cell’s membrane resulting in leakage of intracellular solutes and 
colloid-osmotic lysis of the cell [37]. Pneumolysin stimulates the production of TNF-alpha and 
IL-1β by human monocytes [149], and it may activate the classical complement pathway. It 
also inhibits the chemotaxis of polymorphonuclear leukocytes, thus facilitating the survival of 
pneumococci [308]. Antibodies to Ply appear to reduce the fatality of pneumococcal infections 
in mouse models, but do not necessarily protect against the infection [308, 309]. The Ply has, 
however, been shown to enhanche protection provided by PspA or CbpA in a murine model  
[296].  
 
Pneumococci undergo a spontaneous phase variation between opaque and transparent colony 
morphologies. By means of this phase variation, the bacterium adapts to survive on the 
mucosa or to invade. The phase variation involves modification of several cell wall structures 
including CPS, teichoic acid, choline, and proteins [179, 301, 407]. The transparent phenotype 
with less capsule, more choline and more adhesin CbpA possesses a better ability to colonise 
the nasopharynx as it binds more effectively to the glycoconjugate receptor in the oral 
epithelial cells and to the PAF receptor in the cytokine activated lung cells or endovascular 
cells than the opaque phenotype [69]. The transparent phenotype is also more efficient in 
invading meninges [333]. The opaque phenotype, on the other hand, has improved virulence 
and survival in the blood [179], as it bears less choline and more PspA. It is also more resistant 
to phagocytosis, as it requires 1.2 to 30-fold more immune human serum in order to achieve 
50% killing of opaque phenotype pneumococci in an opsonophagocytic assay compared to the 
transparent phenotype [178].   
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2. Pneumococcal infections in children 
 
2. 1. Nasopharyngeal carriage 
 
Development of pneumococcal carriage Pneumococci cause a wide variety of infections, 
ranging from common mucosal infections, such as otitis media, sinusitis and conjunctivitis, to 
systemic infections including septic arthritis, endocarditis, pneumonia, bacteremia and 
meningitis. The most common entry point for pneumococci is the nasopharynx, where it can 
establish symptomless colonisation or from which it can spread to the respiratory system or 
invade to the bloodstream [112]. Several adhesive components of pneumococcus are important 
in establishing the colonisation. Among those are PsaA, PspA, neuramidase, pyryvate oxidase, 
PspC and other choline binding proteins [45, 46, 49]. An increase in teichoid acid expression 
correlates with an enhanced ability of transparent phase variants of pneumococci to colonise 
[179]. The expression of capsular PS is also essential for the colonisation, but even those 
bacteria with reduced levels of capsule can remain highly virulent [234]. The adhesion of 
bacteria on respiratory mucosa requires glycoconjugate receptors bearing N-
acetylgalactosamine B1-3 galactose, N-acetylgalactosamine B1-4 galactose, and siliac acid 
[13, 69, 70, 279, 407]. Viral respiratory infections appear to enhance the adhesion [130]. The 
process of colonisation can occur simultaneously for several pneumococcal serotypes [122]. 
 
Epidemiology of pneumococcal carriage In general, the results obtained in different 
carriage studies may not be directly comparable. In community studies the nasopharyngeal 
samples are usually collected from healthy children whereas in some hospital-based studies 
the samples may be collected from children attending clinics for diseases such as acute 
respiratory infections and AOM, which are associated with increased carriage rates. Also, the 
techniques for collecting samples, culture media and storage conditions used, and the 
serotyping process may vary in different studies. The WHO Working Group, including 
representatives from different pneumococcal research groups, has described a standard 
methodology, which should reduce the methodological variation in different study settings 
[289].    
 
Pneumococcal carriage is most common among young children. The carriage rate increases 
gradually with age and peaks during the second year of life, after which it gradually decreases 
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to the adult rate of 20-30%, or less [15, 77, 109, 122]. In most developing countries and also in 
indigenous populations in some industrialized countries, the acquisition of pneumococci 
occurs during the very first months of life [121, 159, 163, 188, 380, 427] whereas in most 
industrialized countries the time of first colonization with pneumococcus more commonly 
occurs during the second six months of life or beyond (Figure 1) [15, 175, 396].  
 
The risk for pneumococcal carriage acquisition is increased in crowded conditions, common in 
poor countries with large families of low socio-economic status and inadequate housing [121, 
216, 276]. Similarly, the high risk for carriage acquisition and epidemics of mucosal and 
invasive pneumococcal infections have also been demonstrated in institutions such as military 
training camps, prisons, nursing homes and, importantly, in day-care centres [59, 321, 397, 
413]. Other risk factors include other young siblings in the family, lack of breastfeeding, 
parental smoking and respiratory infections [97, 109, 216, 220, 321, 395]. The age of the host, 
presence of anti-pneumococcal protein and PS antibodies, and the immunogenicity of the 
serotype in question are probably the most important factors determining the duration of the 
pneumococcal carriage [122]. The carriage may be followed by appearance of type-specific 
anti-pneumococcal antibodies [124, 382].  
 
Figure 1. Point prevalence of pneumococcal nasopharyngeal carriage in community 
 based studies among children < 12 months of age 
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References: Papua New Guinea [121], Costa Rica [427], South India [159], Finland [396], the 
Philippines [277]. 
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The rate of colonization of strains with reduced susceptibility to antimicrobials vary by 
population and population subgroups [329, 443]. It correlates with recent antibiotic usage [73, 
77, 216, 328] and the overall use of antibiotics in the community [186, 245]. Most of the 
resistant strains belong to the common paediatric serogroups 6, 14, 19 and 23 [19, 443]. 
 
Serotype distribution Pneumococcal serotypes causing infections vary according to age, 
disease and geographic regions. Serogroups 6, 14, 19 and 23 are commonly referred to as 
paediatric serotypes, as they cause infections mainly in infants and toddlers [92, 122, 135, 
335]. The diversity of serotypes causing infections seems to increase with age. Serotypes 1-5, 
8, 9 and 13 become more common in adulthood [135]. Serotypes/groups 1-3, 5, 7, 12, 14, 16, 
25, 28, 36, 43, 46 and 47 are more often associated with invasive diseases, and serotype 3 with 
a fatal outcome [134, 145, 231]. Serogroups 6, 10, and 23 are more often isolated from the 
cerebrospinal fluid and serogroups 3, 19, and 23 from the middle ear fluid (MEF) [134].  
 
The serotype distribution varies in different countries. Serotypes 4, 6A, 6B, 14, 7F, 14, 19A, 
19F and 23F appear to be globally important, whereas serotypes 1 and 5 are mainly found in 
developing countries, and type 18 only in industrialized countries [22, 120, 135, 231, 344, 
358]. Interestingly, the serotype distribution causing invasive infections may have changed 
during the past decades. In the U.S., the proportion of infections caused by types 1, 2, 3 and 5 
has decreased from 71% to 7%, and 18% to 2% in adults and children, respectively, from 1928 
to 1998 [102].  
 
The wide use of antimicrobials has caused a global emergence of beta-lactam –resistant 
pneumococci [74, 157]. The proportion of penicillin-resistant strains is currently 20% to 100% 
in France, Israel, Romania, Spain, USA, and in many Asian countries [77, 156, 216]. The 
relation of in vitro resistance of pneumococci to antimicrobials with the clinical outcome of 
the infection is not clearly defined [303]. The treatment of infections caused by non-
susceptible strains may require use of more expensive alternative antibiotics and may thus 
result in increased medical costs [318]. If the resistance to penicillin and other antimicrobials 
continues to increase, pneumococcal vaccination may provide the only feasible method to 
control the burden of pneumococcal diseases [44, 61, 185].      
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Risk factors  Several risk factors for pneumococcal infection have been identified. The non-
immunological deficiencies include suppression of cough reflex by alcohol, opiates, or aging 
and the damage to the clearance mechanisms by exposure to cigarette smoke or air pollutants 
[180, 280, 294]. Pneumococcal infections are more common in certain ethnic groups such as 
in American Indians [66], Alaskan Natives [85], Australian Aboriginals [406] and in black 
persons [298]. Whether this is due to genetic susceptibility or other environmental and socio-
economic factors is difficult to determine. The HIV -infection increases the risk of invasive 
pneumococcal infections by 3 to 22 –fold [14]. Other risk factors associated with increased 
risk of invasive pneumococcal infections are listed in Table 1. 
 
Table 1.  Medical conditions associated with an increased risk of invasive pneumococcal 
            infections in children   
 
Prematurity1 
Sickle Cell Disease2 
Other hemoglobinopathias 2, 3 
Congenital or surgical asplenia 4 
Immunocompromised children 3 
HIV infection 5, 6 
Chronic renal failure, nephrotic syndrome 7 
Hypogammaglobulinaemia 7 
Organ or bone marrow transplant 8 
Cancer, especially haematological malignancies 8 
Immunosuppressive treatment 8 
   
References: [367]1, [299]2, [298], [168]4, [14]5, [35]6, [255]7, [1]8 
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2. 2. Acute otitis media 
 
Pathogenesis Acute otitis media (AOM) is a result of complex interaction between pathogen 
and host responses [262]. Epidemiologic, microbiologic and immunologic studies indicate that 
AOM occurs concurrently with, or immediately after a viral upper respiratory tract infection 
[140]. Viral respiratory infections increase the adherence of bacterial pathogens to the 
nasopharyngeal mucosa and impair the function of the Eustachian tube, resulting in negative 
middle ear pressure and capillary leakage of fluid into the middle ear [42, 242, 312]. The 
symptoms of middle ear infection are derived from the activation of inflammatory defence 
system [60]. Clinical AOM is consequently defined as a condition where both acute ear-
related symptoms and signs of middle ear fluid must be present [182]. 
 
 A bacterial pathogen can be isolated from the middle ear fluid (MEF) in two thirds of AOM 
cases in children. The three most common bacterial pathogens are: Streptococcus pneumoniae, 
Haemophilus influenzae and Moraxella catarrhalis [60, 111, 152, 156, 176, 230]. 
Pneumococcus, which causes 30-50% of the culture positive episodes [111, 176], is the most 
virulent organism based on its ability to cause inflammation and symptoms [264]. Respiratory 
syncytial virus (RSV), parainfluenza virus, influenza virus and human rhinovirus are the most 
common viral pathogens detected in the MEF samples [141, 314, 315].  
 
Nasopharyngeal acquisition of a pathogen is a major risk factor for AOM. Children who have 
the highest rate of nasopharyngeal colonization during the first months of life are thus at 
greater risk for an onset of AOM [96, 208]. Other recognised risk factors such as day care 
attendance, the presence of siblings, parental smoking, lack of breast feeding, and pacifier use 
are also associated with an increased risk for viral respiratory tract infections and carriage 
acquisition of bacterial pathogens [306, 323, 401]. Therefore, the independent effect of each 
risk factor is difficult to estimate.  
 
Epidemiology Acute otitis media is the most common bacterial infection in childhood with a 
majority of children experiencing one or more episodes of AOM during the first two years of 
life [183, 323]. The peak age-specific incidence of AOM occurs between 6 and 12 months of 
age [170, 171, 176, 306, 375]. In the Finnish Otitis Media Vaccine study (FinOM), the rate of 
AOM was 1.4 per person-year among children less than 2 years of age [176]. In the U.S., the 7 
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million annual AOM episodes account for 24 million or 17% of all ambulatory care visits in 
children under five years of age [2, 392]. Otitis media is also the most common indication for 
antibiotic treatment in industrialised countries, despite its mostly self-limiting nature [83]. 
Furthermore, chronic otitis media is the most common indication for surgical operation in 
children in the U.S. [302]. Up to 30% of children under two years of age have been reported to 
have undergone ventilation tube surgery within a one-year follow up [269].  
 
The epidemiology of AOM is not well studied in developing countries [34]. While the 
incidence of AOM appears to be at least similar as in industrialized countries, several 
community-based studies have shown that the sequelae of AOM are more common in 
developing countries. The perforation of tympanic membrane has been present in 0.4% – 
33.3%, otorrhoea in 0.4% – 6.1%, and mastoiditis in 0.19% – 0.74% of children [34, 297, 
327]. Otitis media and its complications are estimated to cause 51 000 deaths annually, of 
which the great majority occur in developing countries, as well as substantial hearing 
impairment and learning disabilities [34]. The prevalence of significant hearing impairment 
among primary school aged children has been from 7% to 14.1% in studies conducted in India, 
Nigeria and Tanzania [297, 327, 366]. 
 
 
2. 3. Pneumonia 
 
Pathogenesis The pathogenesis of pneumococcal pneumonia is not fully understood. 
Pneumococcus gains access to lungs from the nasopharynx via aspiration. The preferred target 
for the adherence of the bacteria in the alveolus is the type II cell [68]. The initial attachment 
to the pulmonary epithelium is directed by phosphorylcholine [279]. The choline on teichoic 
acid can serve as a direct ligand to the PAF receptor, which appears on the human cell surface 
following an inflammatory stimulus [68]. The choline also serves as a docking station for a 
family of choline binding proteins (CBPs) such as CbpA1 [339], PspA [244] and autolytic 
enzyme [339]. The interaction of the pneumococcus with the PAF receptor in activated 
epithelial cells is a key step in the transition to intracellular invasion and subsequent 
progression of pneumonia to bacteremia [68, 279]. The progression of adherence to disease 
may also require additional pre-existing events such as viral respiratory infection [130, 317] or 
damage caused by cigarette smoke [326].  
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The progression of pneumococcal pneumonia in animal model is presented in Table 2. The 
increase in epithelial permeability leads to the formation of serous exudate (engorgement 
stage), which progresses to red hepatisation as erythrocytes leak into alveoli in the absence of 
leukocytes. Later, when leukocytes migrate into the consolidated area, the lung exhibits grey 
hepatisation or fibrinous consolidation [279]. The severity of illness needs not correlate with 
the extent of pulmonary consolidation.  
 
Pneumolysin is the major toxin contributing to the pathogenesis of lung injury. It causes 
haemolysis, suppression of ciliary beat, activation of phospholipase, changes in the 
ultrastructure of type I alveolar cells and inhibition of the respiratory burst of leukocytes [248]. 
Pneumolysin and pneumococcal cell wall components, such as phosphorylcholine and 
lipoteichoic acid, can activate the alternative complement pathway [422], which further 
contributes to oedema and fibrin depositions. Pneumolysin also induces with interaction of 
CD14 secretion of cytokines [57]. Although the intense leukocyte response to pneumococcus 
depends also on the number of bacteria in the alveolus [131], the main chemokines enhancing 
the influx of leukocytes are PAF and C5a [53]. Once in the alveolus, the polymorphonuclear 
leukocytes pin the bacteria against the alveolar wall in order to engulf them in a process called 
surface phagocytosis [428].  
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Table2.  Progression of pulmonary pneumococcal infection in a mouse model 
 
Stage I (0 - 4 hours)  
 
The infection is established, although yet asymptomatic. The phagocytosis by alveolar macrophages is 
ineffective and cannot eradicate pneumococci from the alveoli. Cytokines are released: TNF, IL-6 and 
NO predominate in the broncho-alveolar lavage (BAL) fluid, IL-1 in lung tissue and IL-6 in the serum. 
No cell recruitment is yet observed.  
 
Stage II (5 – 24 H) 
 
Multiplication of the pneumococci in the alveoli. The neutrophil chemotaxis begins and is mediated by 
the complement–activating properties of pneumolysin, CPS and cytokines. 
 
Stage III (25 – 48 H) 
 
The phagocytosis of pneumococci is now more effective, but the cytolytic action of pneumolysin 
results in alveolar injury and interstitial oedema. The infection may progress from pre-septicaemic 
stage to the sepsis with bacteria shifting from the alveoli through lung tissue into the blood stream. The 
regeneration process starts with type II pneumocytes proliferating to regenerate both type I and type II 
cells. 
 
Stage IV (49 - 72H) 
 
A sharp increase in alveolar monocyte and lymphocyte activity. The inflammatory and leukocyte 
responses continue increasing, although the rate of bacterial multiplication is already decreasing. 
 
Stage V (> 72 H)  
 
Further proliferation of pneumococci, massive tissue damage and high mortality. An antibody 
response detected 1 – 3 weeks from the onset of infection 
 
References [33, 82] 
 
Diagnostic considerations  Pneumonia can be defined as an inflammation of lung tissue 
due to an infectious agent stimulating an inflammatory response that damages the lung tissue 
[341]. The diagnosis of pneumonia is difficult to standardise due to an array of tests available 
to detect the inflammation of lungs and potential aetiology of infection. In many developing 
countries with limited diagnostic facilities available, the acute lower respiratory tract 
infections (ALRI) are managed by using simple clinical signs and symptoms as defined by the 
WHO in 1982 [429]. The ALRI is defined as cough or difficult breathing simultaneously with 
increased respiratory rate (>50 per minute in infants less than 12 months of age, and > 40 per 
minute in children aged 12 to 59 months). This definition has > 90% sensitivity and 50%-60% 
specificity in detecting those ALRI cases, which present with radiological findings suggesting 
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a bacterial infection [429]. Studies in developing countries have demonstrated that the simple 
case management guideline based on the ALRI definition has reduced mortality by 25% in 
children less than 5 years of age [351].  
 
In most industrialized countries, the golden standard for the diagnosis of pneumonia is chest 
radiograph. The interpretation of radiographs is, however, often difficult as universally agreed 
definition for radiologically confirmed pneumonia does not exist. The WHO is currently 
coordinating an exercise to standardise the interpretation of chest radiographs for the diagnosis 
of pneumonia in children [430]. A standardised definition would probably enhance the 
pneumonia disease burden studies as well as allow inter-study comparisons in efficacy of 
vaccines preventing pneumonia. 
 
Pneumococcal pneumonia is difficult to diagnose. The most specific methods for detecting 
bacteria as a causative agent for pneumonia are blood culture and transthoracic needle 
aspiration method. Unfortunately both methods have their limitations. Detection of bacteria by 
blood culture is specific, but lacks sensitivity. A review of European studies showed that only 
1% to 8% of children with community acquired pneumonia had pneumococci isolated in blood 
culture [341]. Lung aspirate is an invasive procedure, which is limited to those patients who 
have an area of consolidation in the lungs that is accessible to percutaneous needle aspiration. 
On the other hand, the lung aspiration may be able to detect also non-bacteremic 
pneumococcal pneumonia [436]. The review of 12 different studies with lung aspirate samples 
showed that pneumococcus was the most common bacterial cause of pneumonia, but the 
isolation rates varied widely from 1% to 54% [437].  
 
The culture of sputum, nasopharyngeal swabs and urine, sputum or blood antigen detection 
tests or PCR techniques are non-specific, especially in children, and do not reliably 
differentiate between lower respiratory infection and carriage of bacteria in the upper 
respiratory tract [3, 167, 341]. On the other hand, the nasopharyngeal swabs are very useful for 
detecting virus as possible cause of pneumonia [341]. Elevated titers for pathogens in 
serological tests may reveal anamnestic responses to previous infections or vaccination [143]. 
In a study by Lankinen et al [204], the determination of pneumolysin IgG antibodies bound to 
immune complexes showed 51% positivity rate for pneumococci among children hospitalised 
due to pneumonia. As this result required three separate serum samples collected during the 
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disease episode, and the value of single sample was limited, the clinical usefulness of the 
method requires further studies.  
 
Other non-specific tests for bacterial pneumonia include chest radiograph and erythrocyte 
sedimentation rate, white blood cell count, IL-6 and acute phase proteins such as C-reactive 
protein (CRP) and procalcitonin (PCT) [166, 278, 405]. In general, dense alveolar infiltrates 
suggests bacterial pneumonia whereas interstitial infiltrates are associated with viral or mixed 
viral-bacterial pneumonias. However, the findings overlap considerably. Korppi et al [191] 
demonstrated that alveolar infiltrates had 0.41 sensitivity and 0.42 specificity to differentiate 
pneumococcal pneumonia from other pneumonias. A Finnish study [190] did not find 
statistically significant differences between the leukocyte and granulocyte counts in those with 
alveolar and interstitial pneumonia, or in those classified as having pneumonia of bacterial, 
viral, mixed or unknown etiology. However, a greater proportion of those diagnosed to have 
bacterial pneumonia had white blood cell count greater than 10,000/cu.mm or granulocyte 
count greater than 5000/cu.mm or elevated erythrocyte sedimentation rate, but again with 
considerable overlap [190]. The CRP concentration was significantly higher in patients with 
alveolar pneumonia, compared to those with interstitial pneumonia. In another Finish study 
[423], the CRP value > 80 mg/L combined with the interpretation of the chest x-ray had a 
sensitivity and specificity of 0.46 and 0.78 in differentiating between bacterial and non-
bacterial community acquired pneumonia. A study with PCT [254] found that with a cut-off 
value of 1.0 ng/L, the PCT had sensitivity and specificity of 0.86 and 0.88, respectively, for 
bacterial pneumonia. In another Finnish study [405], PCT ≥ 2.0 ng/ml, CRP ≥150 mg/l or IL-6 
≥ 40 pg/ml had the specificity ≥ 80% for bacterial pneumonia. The respective sensitivities for 
bacterial pneumonia with these cut-off values were 50% for PCT, 31% for CRP and 34% for 
IL-6. 
 
Epidemiology  According to WHO estimates, the ALRIs including measles associated 
pneumonia cause 20 – 25 % of the global estimate of 12 million annual deaths among children 
less than 5 years of age (Figure 1) [108, 222, 260]. Over 95% of these deaths occur in 
developing countries. Considering diagnostic difficulties, effect of age, season of the year and 
mixed bacterial-viral infections, most studies have concluded that pneumococcal pneumonia 
accounts for 20% to 40% of all community-acquired ALRI in both industrialised and 
developing countries [4, 87, 110, 127, 167, 217, 331, 341, 359, 361, 362]. The incidence of 
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ALRI varies widely in different countries. Community based studies using the WHO 
definition for ALRI in six developing countries showed incidence of 104 to 1768 new 
episodes per 1000 child years [359]. Hospital based studies in industrialized countries have 
shown far lower incidence of pneumonia with 36-40 episodes per 1000 child years [161, 263]. 
According to a study by Heiskanen-Kosma et al [143], the annual incidence of pneumococcal 
pneumonia in Finland was 5.4 to 10.1 per 1000 child years depending on the age of the 
children.  
 
Figure 1. Major causes of childhood mortality in 1995 [429] 
 
 
 
 
An alternative approach to determine the disease burden attributable to different causative 
agents of ALRI is to use a vaccine study as an epidemiological probe. Mulholland et al [258] 
demonstrated an efficacy of 21 % in reduction of radiologically proven ALRI in Gambia with 
a Hib conjugate vaccine (PRP-T). This information led to an estimation of Hib disease burden. 
The incidences of pneumonia and meningitis caused by Hib were 1250 and 250 per 100 000 
child years, respectively. The incidence of pneumococcal pneumonia was extrapolated to be at 
least three times higher than that of Hib [257]. A Hib effectiveness study with PRP-T vaccine 
in Chile demonstrated similar results with 22% to 26% reduction in suspected bacterial 
pneumonia cases [202]. The Kaiser Permanente Northern California study with 7-valent 
pneumococcal conjugate vaccine (7-PncCRM) reported 20.5% effectiveness against 
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radiologically proven pneumonia in children less than 5 years of age [41]. In South Africa, the 
9-valent formulation of the same vaccine demonstrated 24.9% reduction in radiologically 
confirmed ALRI cases [184]. In all of these vaccine studies, the reduction in pneumonia 
diagnosed by using only clinical signs and symptoms has been <10%. This demonstrates how 
the definition of pneumonia is critical to the observed vaccine efficacy and to the estimates of 
the disease burden.  
 
 
2. 4. Invasive pneumococcal diseases including meningitis    
 
Invasive pneumococcal disease (IPD) is defined as isolation of pneumococcus from blood, 
cerebrospinal fluid or another normally sterile body site. Pneumococcus gains access to the 
systemic circulation via pulmonary capillaries or from the cervical lymphatics through the 
vascular endothelial cells. It cannot enter resting vascular endothelial cells [70], but the 
activation of these cells by inflammation may result in invasion [71]. Bacteremia is the most 
common form of invasive pneumococcal disease [92]. In about 15% of bacteraemias, 
pneumococcus enters the blood stream directly without any obvious focus or carriage [25]. 
The case fatality rate for IPD has varied from 1.3% to 6.6 % in different studies [72, 92, 335]. 
 
Epidemiology The incidence of IPD is highest in very young infants, elderly and in certain 
high-risk populations (Table 3). In a recent report of Active Bacterial Core Surveillance 
(ABCS) in the U.S., the annual incidences among children less than 2 years of age were 166.9, 
120.3, 7.5 and 24.0 per 100 000 for all IPD, bacteremia, meningitis and culture-proven 
pneumonia, respectively [335]. In an earlier Finnish study, the incidence of bacteremic 
pneumococcal disease was 32.8 and meningitis 3.5 per 100 000 among children less than 2 
years of age [92]. In general, the incidence of IPD in the U. S. is 4-8 fold higher than that 
reported for Western European countries. This might be explained by variability in blood 
culturing rates, in antibiotic resistance levels, and in the precise age distributions of the 
populations studied [135]. In most developing countries, the incidence of IPD is higher than in 
Europe or in the non-indigenous populations in the U.S. In South Africa, the annual incidence 
of IPD was 41 per 100 000 children among HIV–uninfected and 2046 among HIV-infected 
children less than 2 years of age [233]. In Gambia, the incidence of IPD was 224 per 100,000 
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child years among children 2 to 11 months of age and 139 among children 12 to 23 months of 
age [411]. 
 
Table 3. Comparative rates of invasive pneumococcal infections in different ethnic 
groups of healthy US children, expressed as the number per 100 000 population 
                          
                                                   Age (months) 
 
Population 0 – 5 6 - 11 12 - 23 24 - 35 36 - 47 48 - 59 ≥ 60 
 
U.S1  73.4 227.8 184.2 64.7 26.7 14.3 5.7 
African  163.5 542.2 440.7 116.4 46.1 20.6 9.3 
American1                     
                                                  Age (months) 
 
 0 – 23 24 – 59 60 – 107 
 
Apache2 1820 227 54 
Alaskan3 624  98  23                           
                                                    Age (months) 
 
 0 - 11 12 – 23 
 
Navajo4 664 453 
 
References 1-4: [1, 66, 85, 298] 
 
Meningitis Pneumococcal meningitis usually occurs with a high-grade or prolonged 
septicaemia. Whether the meningeal invasion is a result of specific targeting or purely a 
change process remains yet unclear [112]. The molecular mechanism by which the bacteria 
gains access across the blood-brain barrier involves the action of pneumococcal adhesins, 
CbpA and choline with the PAF-receptor [112, 333]. The following inflammatory activation 
results in migration of pneumococci through the cerebral microvascular endothelium [333]. 
The transparent phenotypes are 3 to 5 times more efficient in invading endothelia than the 
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opaque phenotypes, in contrast to the bloodstream where opaque phenotypes are more 
invasive [333].    
 
Pneumococcus by itself does not cause direct cerebral cytotoxicity. The tissue damage is a 
result of inflammation and its sequelae stimulated by the components of pneumococcal cell 
wall techoic acid and peptidoglycan, as well as the pneumolysin. The cytokine release opens 
the tight junctions between brain capillary endothelial cells allowing an influx of serum 
components such as chemotactic complement factors, which then attract neutrophils across the 
blood-brain barrier [409]. The resulting inflammatory reaction causes increased intracranial 
pressure, cerebral oedema and alterations of CSF hydrodynamics [408]. This eventually leads 
to reduced cerebral blood flow, ischaemic necrosis and neuronal loss from energy failure 
[347]. Pneumococcal meningitis is associated with higher rates of death and neurologic 
sequelae, such as loss of hearing, than either Hib or Neisseria meningitidis infection [26, 311].  
 
Meningitis represents approximately 15% of IPD [169]. Following the introduction of Hib 
conjugate vaccines, but prior to the introduction of 7-PncCRM vaccine, the pneumococcus 
was the most common pathogen causing meningitis in children less than 2 years of age in the 
U.S. In developing countries, pneumococcus, with the exception of epidemics caused by 
Neisseria meningitidis, is the most common cause of bacterial meningitis [219, 256, 298, 369].  
 
 
3. Immunological protection against pneumococci 
 
3. 1. Host defence mechanisms 
 
Host defence mechanisms against pneumococcal infection consist of both non-immunological 
and immunological mechanisms. The non-specific defence includes normal cough reflex as 
well as intact mucosal surface and clearance mechanisms of the upper respiratory tract. The 
immunological mechanisms can be further divided into specific and nonspecific defence. In 
the absence of specific opsonizing antibodies, the virulent organisms can be cleared from the 
bloodstream during their slow passage through the sinusoids of spleen. The cytokines 
produced by pulmonary macrophages in response to pneumococcal infection include tumour-
necrosis factor alpha (TNF-α), interleukin-6 and interleukin-1. These inflammatory mediators 
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stimulate production of acute-phase proteins and attract phagocytic cells such as PMNLs and 
macrophages at the site of infection [33]. Opsonization, which is followed by phagocytic 
uptake and killing of bacteria can be achieved by classical, alternative and pulmonary 
surfactant lectin pathways [295, 404, 422]. This does not necessarily require the presence of 
specific pneumococcal antibodies, as other factors such as CRP, capsular PSs, Ply, CPS and 
many other cell-wall components can activate the complement cascade [104, 422]. The 
elimination of pneumococci is, however, greatly enhanced if the antibodies to the capsular 
polysaccharide are present [93, 421, 426]. 
  
The specific defence against pneumococcal infection consists mainly of anti-capsular PS and 
protein IgG antibodies. Binding of antibodies to the PS capsule of pneumococcus leads to the 
activation of the complement cascade, which results in deposition of complement components 
C3b and iC3b (or CR1 and CR3) to the capsular surface of the bacteria [50, 93]. The PMNLs 
and macrophages, which possess receptors for these complement factors, then uptake and kill 
the pneumococcus [117, 421]. In addition to the amount of antibody present, the 
opsonophagocytosis is regulated by the polymorphism of Fc gamma receptors (FcγRII). The 
two allotypic forms of FcγRII, H131 and R131, bind IgG1 with equally high affinity, but only 
FcγRIIa-H131 can effectively interact with human IgG2 [336, 414]. As the carbohydrates of 
encapsulated bacteria, such as pneumococcus mainly elicit IgG2 subclass [116], persons 
expressing only FcγRIIa-R131 receptors of low affinity to IgG2 are more vulnerable to 
pneumococcal infections [445]. The production of IgG2 subclass begins later in childhood 
than that of IgG1 and IgG3, reaching adult levels only by the age of 12 [116, 124].  
 
Secretory IgA is the main immunoglobulin isotype at mucosal surfaces and secretions, such as 
MEF. The occurrence of IgA in nasopharyngeal aspirates and MEF is independent of the 
concomitant presence of the antibody in serum [425]. The IgA may protect against 
pneumococcal infections by interfering with the adherence of bacteria to the epithelial cells of 
the respiratory tract, and by enhancing surface phagocytosis, in which the leukocytes pin 
pneumococci against the alveolar wall in order to engulf them [279]. 
 
Pneumococcal antibodies are actively transferred across the placenta [293, 360]. The transfer 
rate depends on factors such as the mother’s vaccination status, antibody isotype and 
pneumococcal serotype in question. In most studies the concentration of serotype-specific 
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pneumococcal PS antibodies in new-born infants has varied between 30% to 89% of that in the 
mothers  [261, 293, 360]. These early antibodies have been shown to protect against 
subsequent pneumococcal carriage acquisition [261] and AOM [345].  
 
The half-life of maternally transferred antibodies is 5 to 6 weeks. By three months of age the 
antibody concentrations are low regardless of the vaccination status of the mothers [293, 360]. 
The possible protection against severe pneumococcal infections in early infancy may thus be 
short-lived, but nevertheless cover the period during which other vaccination strategies fail to 
protect children. 
 
 
3. 2. Immunity to pneumococcus 
 
Antigens can be assigned to one of two major groups according to their T-cell activating 
capacity: T cell -dependent (TD) or T cell -independent (TI) antigens. Protein antigens, which 
are classified to the TD group, are normally immunogenic already in early infancy. The 
response to TI antigens such as bacterial polysaccharides develops later in childhood. This 
may be due to immaturity of B-cell population in the marginal zone of the spleen, or by the 
low expression of CR2 receptors on the marginal zone B cells in young infants [403]. The TI 
antigens can be further classified into T cell-independent type 1 (TI-1) and type 2 (TI-2) 
antigens [251]. The TI-1 antigens such as LPS function as polyclonal B-cell activators and are 
totally independent of T-cell help. TI-2 antigens, such as pneumococcal capsular PSs, can 
activate antibody producing B cells without antigen-specific T-cell help [251]. The activation 
is, however, regulated by CD1 restricted CD8+ helper T cells [213] and natural killer cells [23, 
378]. Unlike the TD antigens, the TI-2 antigens do not induce immunologic memory, antibody 
isotype switch or affinity maturation [330, 390]. 
  
The concentration of antibodies to capsular PSs increases with age. This development appears 
to be serotype specific and coincides with the carriage acquisition and episodes of 
pneumococcal infections such as AOM [123, 124, 382]. Several studies have tried to link the 
carriage as well as mucosal and invasive pneumococcal infections to the low pre-existing 
antibody concentration, or to the subsequent antibody responses. The nasopharyngeal carriage 
of pneumococci induces antibody responses in adults [265], but the results have been partly 
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controversial in children under 2 years of age [123, 124, 382]. In a study by Lochard et al 
[226], the low cord blood IgG1, but not IgG2 antibody concentration to type 14, increased the 
likelihood of early onset AOM in infants. In another study by Prellner et al [320], the IgG1 
and IgG2 concentrations were similar in healthy and otitis prone children, but the type-specific 
antibody concentrations were lower against 6A and 19F in otitis-prone children. Systemic 
antibody responses to pneumococcal PSs are rare in young infants with AOM [424], but 
increase with age [195, 381]. The mucosal IgA responses to AOM develop earlier than 
systemic IgG responses [374]. Similarly to the nasopharyngeal carriage, serotype specific 
antibody concentrations have been shown to increase substantially in bacteremic pneumonia in 
adults [265], but not in all young infants with bacteremia or meningitis [322].  
 
The quantity and quality of antibodies required for protection against pneumococcal infections 
remains unknown. It may also be different for each serotype, and vary for mucosal and 
invasive infections as well as in different populations and epidemiological settings [215, 172]. 
In addition to the serotype specific IgG antibody concentration, the distribution of IgG1/IgG2 
subclasses [18, 384], IgG avidity [16, 17, 18, 394], opsonophagocytic activity [337, 421] and 
animal models [160, 342, 389] have been utilised in order to determine the protective 
immunity. Antibodies to pneumococcal proteins may also have an important role in providing 
protection. The main proteins and toxins that have been shown to confer protection in animal 
models include PspA, PspC, PsaA, Ply, pneumolysoid (PdB and PdBD), pneumococcal 
histidine triad (Pht), autolysin C, CbpA, 29 kDa C3 protease, BVH-3 and BVH-11 and 
putative proteinase maturation protein A [45, 46, 47, 300, 309, 398, 435].  
 
 
3. 3. Measurement of immune responses   
 
Several methods have been developed to measure immune responses to pneumococcus. The 
earlier standard method for determining the concentration of anti-pneumococcal antibodies 
was radioimmunoassay (RIA) [352]. The major drawback of this method was the inability to 
distinguish between different antibody isotypes, and between anti-PS and anti-CPS antibodies 
[193, 267].  
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Enzyme immunoassay  The currently recommended enzyme immunoassay (EIA) 
method is sensitive and convenient if automated for vaccine immunogenicity studies with a 
large number of samples analysed [192, 371]. The EIA allows the determination of IgA, IgG 
and IgM isotype concentrations, IgG subclasses and antibody avidity [17, 324, 384]. The 
International Collaboration on Standardisation of Immunologic assays started in 1994. This 
collaboration has concentrated on developing common methodology and standardisation 
procedures for the pneumococcal EIA used in different laboratories world-wide [316]. The 
future task of this collaboration is to provide similar standardisation also for the 
opsonophagocytic assay. 
 
Unfortunately, the current EIA method has its limitations. Antibodies to pneumococcal PSs 
are not always specific. The antigens used in the EIA method may contain protein and other 
impurities, which affect the results. Also, several pneumococcal serotypes have similarities in 
their capsular PS antigen structures. This can result in serological cross-reactivity between 
different serotypes [385, 447]. Similarly, cross-reactivity has also been reported between 
pneumococcal PSs and PSs from enteric and nasopharyngeal bacteria such as group B 
streptococcus (GBS) [129, 137, 138, 211, 212], as well as food antigens. The correlation 
between IgG PS antibody concentration measured by EIA and the opsonophagocytic capacity 
of antibodies has been good in sera collected from individuals immunised with polysaccharede 
or conjugate vaccines [412, 421]. In non-immunised individuals the correlation has been 
poorer, which could be interpreted as presence of polyreactive or unspecific antibodies with 
lower protective efficacy [18, 271, 385, 447]. The removal of the polyreactive antibodies by 
inhibition with an irrelevant PS such as 22F may improve the specificity of antibodies [64, 
385].    
 
Avidity  The assay for the avidity of antibodies measures the relative strength of the 
binding between the antibody and antigen. The low avidity antibodies dissociate with lower 
concentration of thiocyanate (NaSCN) than the high avidity antibodies [16, 17, 116]. In Hib 
vaccine studies, the high avidity antibodies have been superior in functional activity [119]. 
The high avidity is also associated with increased protection in an experimental Hib infection 
model [229]. Pneumococcal vaccine studies have demonstrated that a lower concentration of 
high than low avidity antibodies is needed for the phagocytosis of pneumococci [16].  
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Opsonophagocytic assay The measurement of opsonophagocytic activity (OPA) of 
antibodies is a method for assessing the functional capacity of antibodies in phagocytosis of 
pneumococci. As the host’s protection against pneumococcal infections is mainly mediated by 
phagocytosis, the functional activity of antibodies in enhancing the uptake of pneumococci 
and/or killing, rather than just the concentration of antibodies, may correlate better with the 
efficacy needed to prevent infections. This has been demonstrated in animal models [160, 342, 
343], but not yet in vaccine efficacy studies. The OPA method has demonstrated age 
dependent differences in response to pneumococcal polysaccharide vaccine in the elderly 
[338], low functional activity of conjugate vaccine induced antibodies in bone marrow 
transplant recipients [307], and different responses to conjugate and polysaccharide vaccines 
in children and adults with sickle cell disease [418].  
 
A variety of techniques measuring the OPA have been developed. These include radioisotopic, 
flow cytometric, microscopic and viability (killing) assays with human PMNLs or culturable 
phagocytes (differentiated HL-60 cells) as the effector cells, with or without the addition of 
external complement [43, 93, 158, 227, 237, 238, 270, 337, 421].  
 
 
 4. Pneumococcal vaccines 
 
4. 1. Development of pneumococcal vaccines  
 
The first clinical trial with a Pneumococcal vaccine was conducted in South Africa in 1911. 
The objective of that study was to prevent epidemic pneumonia in gold miners with a vaccine 
containing whole heat-inactivated pneumococci of one or more unknown serotypes [434]. 
During the following decades the protective effect of antibodies against capsular PS was 
discovered [106]. The first type-specific tetravalent pneumococcal PS vaccine including 
serotypes 1, 2, 5 and 7 (4-PncPS) was studied in pneumonia prevention among USA army 
personnel during the World War II [232]. This vaccine was consequently licensed as hexa 
valent version in 1946. The vaccine was, however, abandoned in the early 1950s’ as it seemed 
that the introduction of penicillin would solve the pneumococcal problem. When it became 
obvious that the antimicrobials had only a limited efficacy in treatment of severe bacterial 
infections [20], the interest in pneumococcal vaccines was re-born, leading finally to the 
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licensure of 14–valent PncPS vaccine in 1977 and the currently available 23-valent 
formulation in 1983 [334].  
 
During the 1980s, the limitations in the efficacy of the PncPS vaccines, especially in the high 
disease burden populations, and the success of Hib conjugate vaccines, lead to the 
development of pneumococcal conjugate vaccines [90, 356]. The first 7-valent conjugate 
vaccine (7-PncCRM) was licensed in the U.S. in February 2000 [1]. Currently, the research 
efforts concentrate in developing pneumococcal conjugate vaccines with various carrier 
proteins and wider serotype coverage, pneumococcal protein vaccines, DNA vaccines [249], 
and pneumococcal vaccines, which could be administered intranasally [236].  
 
 
4. 2. Pneumococcal polysaccharide vaccines 
 
The licensed 23–valent PncPS vaccine contains 25 µg of capsular PS from serotypes 1, 2, 3, 4, 
5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
These serotypes cover approximately 90% or more of the pneumococcal serotypes causing 
IPD in most countries [135]. The 23-PncPS vaccine is safe and well tolerated in children and 
adults [214, 235, 332], although adults with high pre-existing antibody concentrations or re-
vaccination are more likely to experience fever and local reactions [155, 350]. 
 
The 23-PncPS vaccine is immunogenic in healthy adults [113], but antibody responses vary 
individually and are often decreased in elderly and immunocompromised individuals [132, 
340, 348, 349]. Also, the functionality of antibodies, when measured by the OPA assay, may 
be reduced and thus the antibodies provide poor protection against pneumococcal infections 
[338, 340]. As the 23-PncPS vaccine does not induce immunologic memory, the persistence of 
antibodies requires frequent revaccinations [349]. Furthermore, studies have demonstrated that 
the 23-PncPS vaccine does not induce herd-immunity by decreasing the carriage rate of 
pneumococci in adults or children [146, 332]. The exception is the reduced carriage of 
pneumococci in infants following the immunisation of mothers during the pregnancy with the 
23-PncPS vaccine [261]. 
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As the response to TI antigens matures with age, the pneumococcal PSs are poorly 
immunogenic in early childhood. Antibody responses also vary according to the serotype in 
question, being poorest in the common paediatric serogroups 6, 14 and 23, and highest in 3, 4, 
8 and 9N [194, 218, 221]. As predicted by the immunogenicity studies, the efficacy of PncPS 
vaccines in preventing pneumococcal infections has been modest or poor in young children 
[86, 400]. The exceptions include a Finnish study [235], in which the overall efficacy in 
preventing AOM caused by the vaccine -type pneumococci among children less than 5 years 
of age who had already experienced one episode of AOM was 58%. No efficacy was, 
however, noticed among children less than 6 months of age. In another study [218], the PncPS 
vaccine prevented 59% (95% CI 19 – 79%) of mortality due to acute lower respiratory tract 
infections among children in Papua New Guinea. Similar protective efficacy against IPD or 
pneumonia has not been demonstrated in other countries [1, 298].  
 
In adults, several clinical trials and meta-analysis have tried to demonstrate the efficacy of 23-
PncPS vaccine in preventing pneumonia and IPD [65, 105, 253]. In a recent meta-analysis 
[105] consisting of 14 randomised clinical trials and 48, 837 cases, the efficacy against 
culture-proven pneumococcal pneumonia was 71% (95% CI 58% – 80%) and against 
presumptive pneumococcal pneumonia 40% (95% CI 4% - 63%). No preventive effect was 
seen against all-cause pneumonia or death, or for any pneumonia in patients aged 55 years or 
more. In a Finnish population based study [187], the overall vaccine efficacy in prevention of 
pneumonia among elderly was 15% (95% CI -43% to 50%) and in persons with medical risk 
factors for contracting pneumonia 59% (95% CI 6% to 82%). An opposite results was noticed 
in Uganda where the 23-PncPS vaccine did not decrease, and might even have increased the 
risk for pneumonia among persons with HIV-infection [107]. The efficacy against IPD in 
young and elderly adults has ranged from 56% to 81% [98, 363, 364].  
 
The CDC Advisory Committee on Immunization Practices (ACIP) recommends the use of 23 -
PncPS vaccine for all persons aged ≥ 65 years and persons ≥ 2 years of age who are at 
increased risk for severe pneumococcal infections because of chronic medical conditions [1]. 
A revaccination is recommended 5 years after the initial vaccination for immunocompromised 
persons and for those aged ≥ 65 years who received the first dose before the age of 65 years. 
The recommendation for vaccination of elderly people with PncPS vaccine has also been 
given in Austria, Belgium, Canada, Denmark, Finland, Iceland, New Zealand, Norway and 
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Sweden [101]. The health authorities in many countries have since 1985 recommended the 
PncPS vaccine for all children over 2 years of age who are at high risk for severe 
pneumococcal infections [2]. This recommendation has been updated following the licensure 
of the 7-PncCRM vaccine. The conjugate vaccine is now recommended as the first option, and 
the 23-PncPS vaccine should be given only if an extended serotype coverage is required due to 
the high risk of pneumococcal infections in children over 2 years of age [11, 142, 281].   
 
 
4. 3. Pneumococcal conjugate vaccines 
 
The method for improving the immunogenicity of PSs by conjugation was developed already 
in the 1920s [21], but utilised only in the 1980s in development of Hib conjugate vaccines. 
The new Hib vaccines, of which the first was licensed in the U.S. in December 1987, were 
found safe, immunogenic and effective in eradicating the vast majority of serious Hib 
infections in countries where the Hib vaccine was included in the national vaccination 
program [136, 355]. The pneumococcal conjugate vaccines have been developed along the 
same principles as the Hib conjugates. The major difference is that the protection against Hib 
infection requires immunity to only one capsular PS, whereas the protection against a 
significant proportion of pneumococcal infections requires immunity to several of the at least 
90 identified capsular PSs. This results in multivalent vaccines, in which each purified 
capsular PS is coupled covalently to an immunogenic carrier protein (Table 4). The amount of 
carrier protein must be sufficient to induce T –cell memory for each PS, but still small enough 
to minimise the induction of anti-carrier antibodies [28]. The excess amount of carrier protein 
may also impair antibody response to the TD antigen through antigen competition or carrier-
mediated epitope suppression [73, 99].  
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Table 4. Pneumococcal conjugate vaccines in phase 2 and phase 3 clinical trials 
 
Vaccine  Serotypes    Manufacturer 
PncOMPC  6B, 14, 19F, 23F; or   Merck 
   4, &b, 9V, 14, 19F, 23F 
 
PncCRM  4, 6B, 9V, 14, 19F, 18C, 23F; or  Wyeth Lederle Vaccines 
   1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F  Pediatrics 
 
PncT   6B, 14, 19F, 23F; or 3, 4, 6B, 9V  Aventis Pasteur 
   14, 18C, 19F, 23F 
 
PncD   6B, 14, 19F, 23F; or 3, 4, 6B, 9V  Aventis Pasteur  
   14, 18C, 19F, 23F 
 
PncT/D   1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F   Aventis Pasteur 
PncPD   1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F   Glaxo SmithKline 
 
Protein carriers: OMPC- Outer membrane protein complex of Neisseria meningitidis, CRM – 
Nontoxic mutant variant of diphtheria toxoid, T – Tetanus protein, D – Diphtheria toxoid, T/D 
– Mixed (tetanus protein or diphtheria toxoid) carrier, PD – Haemophilus influenzae protein D 
[172, 283]. 
 
Immunobiology The conjugation of PS to a protein carrier converts the TI-2 type of 
response to PS antigen to a TD type of response with enhanced immunogenicity [10]. The PS-
carrier protein -complex is captured by dendritic cells (DC), which then process the protein 
into peptides to be presented to antigen specific T-cells in association with MHC class II 
molecules [243, 370]. These T-helper (Th) cells recognise the peptide-MHC II complex by T-
cell receptor and express CD40L [154]. The activation of CD40L then initiates the cytokine 
secretion of DCs and subsequent T-cell proliferation. The Th cells differentiate into Th0, Th1 
or Th2 cells. Both Th1 and Th2 cells induce B-cell responses, but Th1 cells are associated 
with switching of antibody class to IgG2, whereas Th2 cells to IgG1 [240, 377]. The 
pneumococcal and Hib conjugate vaccines induce mixed Th1 / Th2 responses in adults [441].  
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The PS-specific B cells also detect and internalize the PS-protein –complex, and present the 
carrier protein peptides in context of MHC II on their surface [370]. The interaction between 
activated PS -specific B cells and carrier protein -specific Th cells results in proliferation and 
differentiation of B cells into antibody-secreting plasma cells or memory cells [205, 370, 399]. 
The short-lived plasma cells are responsible for the early antibody response consisting mostly 
of IgM antibodies. The antibody isotype switch to IgG class occurs when B cells proliferate in 
lymphoid tissue to form germinal centres [32]. The competition for diminishing antigen leads 
to the selection of high-affinity B-cell clones while the low-affinity clones are destroyed by 
apoptosis and macrophage-mediated phagocytosis [32, 114]. This affinity maturation 
continues for 6-7 weeks after the initial antigen presentation [399]. The development of PS –
specific, high-avidity memory B cells requires carrier protein specific Th cells [114, 399]. The 
memory for humoral immunity induced by pneumococcal conjugate vaccines is thus 
dependant of formation of memory B cells and long-living plasma cells [239, 376].   
   
Several characteristics of pneumococcal conjugate vaccines can affect antibody responses. 
These include the chemical characteristics and length of carbohydrates [88, 200, 313], 
properties of the carrier protein [391], the nature and site of the chemical linkage between 
carrier and carbohydrate [391], conformational changes in epitopes after conjugation [88], 
availability of antigen structural components [84], and the carbohydrate: protein ratio [240]. 
The PS –carrier protein formulations are more immunogenic than OS-carrier vaccines [84, 
391].  
 
Some pneumococcal conjugate vaccine formulations include an adjuvant, such as aluminium 
phosphate or hydroxide, which can enhance and promote Th2-type immune responses [88, 
128]. The exact mechanism of the improved immune response remains unknown, but it may 
be related to slow release of antigen at the site of vaccination, or to increased uptake and 
presentation of antigens by antigen presenting cells [128]. While the adjuvants often improve 
the immunogenicity, they also increase the occurrence of local and systemic side effects [128]. 
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4. 3. 1. Immunogenicity and safety studies 
 
The development of pneumococcal conjugate vaccines began with 1-valent formulations [100, 
356], but gradually the valency has increased to eleven-valent vaccines (Table 6). To date, 
different pneumococcal conjugate vaccine candidates have been evaluated in over 70 phase I-
II immunogenicity and safety studies [440]. The main characteristics for the evaluation of 
immunogenicity are mentioned in Table 7. 
 
Table 7. Evaluation of immunogenicity of pneumococcal vaccines 
 
1. The magnitude and persistence of antibody response following the primary series and 
subsequent doses of the vaccine in different age groups 
2. The induction of immunologic memory and avidity maturation 
3. Isotype or IgG subclass distribution 
4.  Functional activity of antibodies 
 
Modified from reference [172] 
 
The pneumococcal conjugate vaccines are immunogenic in infants  [5-8, 80, 89, 151, 173, 
241, 283], toddlers [273, 439] and adults [421, 442], and prime for immunologic memory [6, 
16, 78, 164, 288, 292]. In infants, the elicited IgG antibodies are mainly of subclass IgG1, 
whereas in adults the main subclass is IgG2 [18, 383, 421]. The elicited antibodies are 
functional when measured by OPA and show avidity maturation [16-18, 421]. The 
pneumococcal conjugate vaccines induce modest mucosal immune response as demonstrated 
by the induction of IgA -secreting cells and appearance of salivary IgA and IgG antibodies 
[63, 189, 273, 282]. The vaccines are also immunogenic among those not responding to PS 
vaccines [266, 449], in patients with recurrent respiratory infections [29] and in HIV infected 
individuals [9, 102, 181, 196, 252], lymphoma patients [58, 250], renal transplant recipients 
[197], BMT recipients [388] and in the elderly [228, 319, 365].  
 
None of the published immunogenicity studies were originally designed to compare immune 
responses induced by different pneumococcal conjugate vaccines, or to compare responses to 
the same vaccine in different countries. Such comparisons may, however, be required if the 
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licensure of new pneumococcal vaccines is based on the non-inferiority in immunogenicity 
when compared to the licensed 7-valent PncCRM vaccine [446]. Also, if the serologic 
surrogates for protection against different pneumococcal infections are established, the elicited 
immunogenicity would predict the impact of immunisation on the pneumococcal disease 
burden. The National Public Health Institute laboratory in Finland has analysed samples from 
several immunogenicity studies conducted in Finland with different pneumococcal conjugate 
vaccines (Table 8). The results show a trend towards higher immunogenicity with PncCRM 
and PncPD compared to PncTD and PncOMPC vaccines for serotypes 6B, 14 and 18C, but not 
for serotype 19F.  
 
The comparison of immunogenicity of PncCRM vaccine in different countries (Table 9) 
shows that the vaccine may elicit higher GMCs of antibodies, especially against serotypes 6B 
and 18C, in Africa than in Europe or the U.S. This trend should be interpreted cautiously as 
the age of vaccination concomitant vaccines and pneumococcal epidemiology are different in 
each country [172]. In the U.S. Miernyk et al [246] did not notice clear differences in antibody 
responses to a 7-valent PncCRM vaccine in Alaskan native, Apache and Navajo Indian, and 
non-native, but ethnically heterogeneous American infants.   
 
Most immunogenicity studies have reported antibody responses after three doses of vaccine, 
and following the fourth (or booster) dose. In studies where the responses to each vaccine dose 
have been reported, the poorly immunogenic serotypes 6B and 23F have required 3 doses for 
significant increase in the GMC of antibodies, whereas the highly immunogenic serotypes 4 
and 19F may require only 1 or 2 vaccine doses for significant responses [8, 84, 151, 173, 282, 
372]. The avidity and OPA of antibodies seems to increase with the number of doses [287], 
but already one dose is enough to induce immunologic memory [115, 164, 292]. Both 
conjugate and PS vaccines have been used as a booster following the primary series with a 
conjugate vaccine. The PncPS vaccine with higher PS content (25 µg vs. 2-10 µg ) may induce 
higher GMCs than conjugate vaccines [5]. The avidity might be higher following a booster 
dose of conjugate vaccine [16].  
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 Table 8.  The geometric mean concentration (GMC, µg/ml) of anti-pneumococcal polysaccharide antibodies after three doses of 
 different Pneumococcal conjugate vaccines in Finnish infants         
      
              
Vaccine                Pneumococcal serotype 
             
    1   3    4    5   6B    7F    9V    14   18C  19F   23F   
  
7-PncCRM           
N = 60   -   -  2.9   -  1.4   -  1.8   5.2   2.6   7.1 4.2 
              
7-PncOMPC              
N = 55 - -  3.5  -  0.4   -  1.8   3.2   1.0   3.2   0.7 
 
11-PncTD 
N = 56   1.7   1.1   3.5   1.6   0.6   3.7   1.6   1.0   0.7   4.7   1.2 
 
11-PncPD 
N = 103   2.6   2.3   2.6   1.6   1.4   2.0   2.0   4.8   1.6   4.1   1.5 
     
 
Vaccine given at 2, 4 and 6 months of age. Serum sample collected at 7 months of age. All samples analysed at the KTL laboratory in Helsinki, Finland. 
References: [5, 282, 283, 440] 
 
 
 
 
 
 
 
 Table 9.  The geometric mean concentrations (µg/ml) of anti-pneumococcal polysaccharide antibodies after 
three doses of 7- and 9 valent PncCRM vaccine in infants          
     
              
Population               Pneumococcal serotype 
             
    1      4    5   6B     9V    14   18C  19F   23F     
  
USA   -    1.3    -  1.2     1.0   3.7   1.4   2.0   2.5     
N = 156     
 
Finland      -  2.9        -  1.4         1.8  5.2        2.6   7.1       4.2      
N = 60         
              
UK      -   2.4       -   1.1       1.5   2.2       1.4    2.5       1.5 
N = 112  
 
South Africa    5.8     4.2   7.3   5.6       3.6    3.8       5.7    2.9       3.0 
N = 122   
 
Gambia   6.9     4.9   5.8   4.9       4.1    4.5       4.9    2.9       2.9 
N = 91    
 
 
References: [63, 241, 282, 287, 368] 
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Interference with other antigens Immunogenicity studies have not revealed major 
problems related to simultaneous administration of pneumococcal conjugate and other 
paediatric vaccines [172, 440]. Several studies have, however, reported interactions in 
immunogenicity between different vaccines. Concurrent and mixed administration of 
conjugate vaccines with the same carrier protein appears to lower responses to pneumococcal 
polysaccharides [62, 126]. However, if the carrier proteins are different such phenomenon 
might not occur [174]. The interaction between vaccines might be different for each conjugate 
vaccines preparation. Concurrent administration of acellular diphteria-tetanus-pertussis 
vaccine (DtaP) instead of the whole cell formulation (DTwP) lowered the pneumococcal PS 
antibody responses to 11-PncTD vaccine in Israeli infants [81]. On the other hand, the use of 
DTwP, DTaP, or combination vaccines, such as DTaP-IPV-HBV/Hib did not interfere with 
responses to PncCRM vaccine [241, 354, 368].   
 
The effect of pneumococcal conjugate vaccines to concurrently administered other vaccines 
has varied. The primary vaccination series with PncCRM with DTP and Hib conjugate 
(HbOC) vaccines enhanced the antibody responses to diphtheria and Hib antigens [62, 84, 
241]. Contradictory, when the PncCRM vaccine was given concomitantly with DTaP-HbOC 
in the booster series, the antibody responses were reduced against all vaccine antigens [287, 
368]. The reduction of anti-pneumococcal and tetanus antibodies, however, remained modest 
and the significant reduction of anti-diphtheria, pertussis and Hib antibodies might be 
clinically insignificant as the antibody concentrations, at least for diphtheria and tetanus, 
remain above protective levels [368]. A high dose of tetanus protein in tetanus-conjugated 
pneumococcal vaccine inhibited responses to tetanus conjugated Hib vaccine and tetanus 
toxoid [73]. Similarly, concomitant administration of Hib and pneumococcal conjugate 
vaccines, both with diphtheria carrier, resulted in decreased Hib response [165, 372]. This 
suppression may be due to protein load and carrier –mediated interference in immunogenicity 
[310]. 
 
Safety The pneumococcal conjugate vaccines appear to be safe and well -tolerated among 
children and adults [90, 298]. No significant safety problems have been reported in so far 
conducted safety and immunogenicity studies with over 20 000 subjects receiving various 
numbers of doses of different vaccine candidates [90, 440]. Local reactions such as redness, 
swelling, induration and pain at the site of injection have been the most common adverse 
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reactions following the immunisation. The rate of local reactions has varied between 6% and 
38% in different studies, but has been lower at the pneumococcal than at the DTP-Hib vaccine 
site (32% to 53%) [91, 246, 368, 410, 439, 442]. Fever above 38.5Ο C has occurred in up to 
52% of children, 22 % in toddlers and 4% in adults [440]. The increased valency of conjugate 
vaccines has not led to an increase in adverse reactions [440]. No increase in the incidence or 
severity of local reactions has occurred when giving the subsequent doses of primary series or 
booster in childhood [78, 290, 368, 410]. 
  
 
4. 3. 2. Efficacy studies  
 
Efficacy against pneumococcal carriage Pneumococcal conjugate vaccines are able to 
reduce nasopharyngeal carriage of serotypes included in the vaccine (Table 10). The reduced 
carriage may lead to the interruption of the transmission of these serotypes in the community 
and thus formation of herd immunity [74, 76]. In a study with American native Apache and 
Navajo children [246], 4 doses of 7-PncCRM resulted in reduction of vaccine type 
pneumococci that lasted at least 3 years, while the overall carriage rates among vaccine 
recipients and controls remained similar. Most studies have indeed reported an unchanged 
overall carriage rate of pneumococci as the carriage of non-vaccine serotypes has increased 
[76, 185, 275, 286]. This serotype replacement could be due to non-vaccine serotypes winning 
the competition for colonisation [225], or by unmasking the sub-dominant serotypes 
previously carried in low numbers [185]. As the vaccine-type serotype strains are often 
resistant to antimicrobials, the use of pneumococcal conjugate vaccines has the potential to 
substantially reduce the number of infections due to resistant pneumococci (Table 8) [185, 
420]. The efficacy against pneumococcal carriage has so far been demonstrated only in young 
children with high carriage rates. As adults and older children are less likely to acquire 
pneumococcal carriage, the demonstration of efficacy in these populations would require large 
sample sizes or special circumstances such as institutions [185].  
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Table 10.  Effect of three doses of different pneumococcal conjugate vaccines on the 
            nasopharyngeal carriage of pneumococci in children 
 
Country Vaccine Age at vaccination Carriage of vaccine serotypes in 
(months)    vaccinees / controls (%) 
 
Gambia 5-CRM  2, 3, 4   50 / 90 (p< 0.001) 
 
Finland 7-CRM  2, 4, 6   9.5 / 16.2  
USA  7-CRM  2, 4, 6   24 / 36 (p< 0.004) 
UK  7-CRM  2, 3, 4   11.2 / 13.5 (NS) 
South Africa 9-CRM  1.5, 2.5, 3.5  18 / 36 (p<0.001) 
Iceland 8-TD   3, 4, 6   26 / 40 (p= 0.0003) 
Israel  11-TD   2, 4, 6   16 / 32 (p= 0.019)  
 
 CRM= CRM197 conjugate, D= diphtheria toxoid conjugate, T= tetanus protein conjugate, TD= mixed 
(diphtheria toxoid or tetanus protein) conjugate vaccine. NS= not significant difference between 
vaccinees and controls. Modified from a review article [185].  
 
Efficacy against acute otitis media  The efficacy of pneumococcal conjugate vaccines 
against AOM have been demonstrated in three larger efficacy studies (Table 11) and in a day-
care study in Israel. In the Finnish Otitis Media Vaccine Trial (FinOM) with the 7-PncCRM 
vaccine, the AOM episodes were defined as signs of acute infection and an abnormal tympanic 
membrane. A middle ear fluid (MEF) sample was collected in 93% of episodes. The overall 
incidence of AOM was 1.16 episodes per person year in the pneumococcal vaccine group and 
1.24 in the control vaccine group. The per protocol efficacy against AOM caused by vaccine-
type pneumococci was 57% (95 % CI 44% – 67%). However, there was a 33% increase in 
AOM episodes caused by the serotypes not included in the vaccine. Although the overall 
efficacy against all clinical AOM was only 6% (95% C, -4% – 16%), the efficacy against 
severe forms of AOM such as spontaneous perforation of tympanic membrane was 69% (95% 
CI 5% – 90%) [304]. The protection against vaccine-type pneumococcal AOM varied widely 
between serotypes, being lowest for 19F (25%) and highest for 6B (84%). The follow-up 
surveillance demonstrated that 7-PncCRM vaccine reduced the tympanostomy tube 
  43
REVIEW OF LITERATURE 
 
 
placements by 39% (95% CI 4% – 61%) [305]. In the U.S., the 7-PncCRM vaccine decreased 
consultations due to frequent AOM by 23% (95% CI 7% - 36%) and tympanostomy tube 
replacement operations by 20% (95% CI 1% - 35%) [39]. The FinOM study with 7-PncOMP 
showed similar results as mentioned above (Table 9). The fourth study to evaluate the effect of 
pneumococcal conjugate vaccine (9-PncCRM) on AOM was conducted among day-care 
attending children in Israel [79]. Healthy children 12 to 35 months of age were randomised to 
receive either 1 or 2 doses of the 9-PncCRM vaccine or meningococcus group C conjugate 
vaccine. After 5556 child months of follow-up, the investigators concluded that the vaccine 
reduced episodes of otitis media, but that the 17 % reduction was not statistically significant 
(95% CI –2% to 22%). The magnitude of the reduction was somewhat larger in children under 
36 months of age (23% fewer episodes; 95% CI –3% to 42%) than in children 36 months of 
age or older (12% fewer episodes; 95% CI –20% to 35%). 
 
Table 11.  The efficacy of pneumococcal conjugate vaccines in prevention of acute otitis 
             media (AOM) episodes in children 
 
Country Vaccine  Efficacy (95% CI) Definition  
Finland  7PncCRM 57 % (44%, 67%) AOM caused by vaccine type Pnc 
    34% (21%, 45%)  AOM caused by Pnc  
    6% (-4%, 16%)  All AOM  
    -33 % (–80%, 1%) AOM caused by non-vaccine type Pnc 
Finland  7PncOMP 56 % (44%, 66%) AOM caused by vaccine type Pnc 
    25% (11%, 37%)  AOM caused by Pnc 
    0% (–4%, 16%)  All AOM 
USA  7PncCRM 8.9 % (6%, 12%)  All AOM visits  
References: [39, 91, 177] 
 
Efficacy against pneumonia The impact of pneumococcal conjugate vaccines in prevention 
of pneumonia is presented in Table 12. In the Kaiser Permanente Northern California study 
[41], the incidences of first pneumonia episodes were 53.4 and 55.9 per 1000 person years in 
vaccine and control groups, respectively. A radiograph was obtained in 61% of episodes. A 
positive radiograph showing consolidation, empyema or parenchymal infiltrate was obtained 
in 21%, and a radiograph with perihilar findings in 5% of episodes. The greatest impact was 
seen during the first year of life with a 32.2% reduction in clinical pneumonia episodes with 
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positive radiograph. The effectiveness decreased with age and was 23.4% during the first 2 
years, but only 9.1% in children > 2 years of age. The race or ethnicity specific pneumonia 
rates were 15.9, 11.6, 11.4 and 8.2 cases per 1000 person years in Asians, Blacks, Hispanics 
and Whites, respectively. Yet there was no evidence of ethnic variation in the vaccine 
effectiveness [41]. The results from the Soweto study in South Africa [184], which are 
currently based on provisional data only, confirm the vaccine efficacy against radiologically 
confirmed pneumonia, but also highlight the modest efficacy against clinically diagnosed 
pneumonia or ALRI.  
 
Table 12.  Efficacy of 7 and 9-valent PncCRM vaccines in prevention of pneumonia in 
 children 
 
USA1 
Radiologically confirmed pneumonia 20.5 % (95% CI 4.4%, 34.0%, p= 0.02) 
Clinical pneumonia with any radiograph 9.8% (95% CI 0.1%, 18.5%, p < 0.05) 
First clinical pneumonia episode  4.3 % (95% CI -3.5%, 11.5%, p= 0.27) 
South Africa2 
Single episode of pneumonia 
with alveolar consolidation   24.9 % (95% CI 3.9%, 41.1%) 
Clinical pneumonia     5.3% (95% CI –2.0%, 12.0%) 
 
1Per protocol effectiveness of the seven valent Pnc CRM 197 conjugate vaccine in preventing 
pneumonia in children less than 5 years of age in Northern California, the U.S. [41]. 2Efficacy of 9-
valent pneumococcal conjugate vaccine on lower respiratory tract infections hospitalisations among 
HIV-1 uninfected children [184] 
 
Efficacy against invasive pneumococcal disease The Northern California Kaiser 
Permanente as well as Navajo and White Mountain Apache studies showed that the 7-
PncCRM vaccine is effective in reducing IPD among vaccinated children (Table 13). The 
post-licensure surveillance has further demonstrated a significant decline in IPD incidence in 
children less than 5 years of age in the U.S. [31, 419]. The incidence of IPD caused by vaccine 
serotypes among children less than one year of age ranged between 51.5 and 98.2 per 100 000 
person years before the immunisation started, and fell to 9.4 after the routine use of 7-
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PncCRM (87.3 % reduction). In children < 2 years of age, the incidence was 81.7 to 113.8 
before, and 38.8 after the introduction (58.1 % reduction) [40]. As the decline was greater than 
expected from the vaccination coverage surveillance, this may indicate the development of 
herd immunity [40, 419]. The Kaiser Permanente study or the post-licensure follow up did not 
show any serotype replacement. In Massachusetts, however, the IPD caused by pneumococcal 
types included in the vaccine declined by 2/3 following the introduction of PncCRM, but the 
IPD due to non-vaccine and non-cross-reactive types increased from the early 90’s situation 
[150]. Whether this indicates true serotype replacement in IPD, or just normal variations in 
epidemiological situations will require further surveillance.   
 
Table 13.  Effectiveness of pneumococcal conjugate vaccines in prevention of IPD among 
 children 
 
Country  Vaccine  Efficacy (95% CI) 
 
U.S. - California 7PncCRM 97.4% (95% CI 82.7% - 99.9%) 
U.S. -Navajo  7PncCRM 76.8% (95% CI –9.4% - 95.1%) 
South Africa  9PncCRM 84.6% (95%CI 32.0% - 98.3%) 
 
References: U.S. California [39], Navajo [291], Provisional data from South Africa [184] 
  
 
4. 3. 3. Licensure and introduction of pneumococcal vaccines      
 
Current recommendations  The 7-valent PncCRM (Wyeth Lederle Vaccines, Pearl River, 
N.Y.) is licensed by FDA in the U.S., by the European Medicines Evaluation Agency (EMEA) 
in the E.U. and by respective regulatory authorities in several other countries including 
Australia, Canada, New Zealand and most countries in Central and South America. In the 
U.S., the Advisory Committee on Immunization Practices (ACIP) [1] and the American 
Academy of Pediatrics [298] recommends the routine use of the vaccine for infants, and for 
limited use in children 2 to 5 years of age. Due to high demand and severe shortages in 
delivery of the vaccine the FDA has issued a new recommendation for limited availability 
situations in December 2001 [420]. The risk groups for whom the vaccine is recommended 
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include all underprivileged children under 5 years of age, and children with sickle cell disease, 
asplenia, splenic dysfunction and HIV infection. Several other countries [353], including 
Finland (Table 14) [281] have issued similar recommendations for use, but due to lack of 
convincing cost-benefit data the vaccine has not been included in the national vaccination 
programs, except for the risk groups, in most of the countries.  
 
Table 14.  Recommendation for the use of 7-PncCRM vaccine in Finnish children 
 
Age  Previous doses  Recommendation 
 
All children 
2-6 months     3 doses 4-8 weeks apart; additional  
      dose at 12 – 15 months of age  
7-11 months     2 doses 4-8 weeks apart; additional  
      dose at 12-15 months of age 
12-23 months     2 doses 8 weeks apart 
 
Risk groups 
24-58 months       4 doses   1 dose of 23PncPS at 2 years of age 
      and 1 dose 3-5 years later 
24-59 months      1-3 doses   1 dose of PncCRM; 1 dose of 
  23PncPS at 2 years of age and 3-5 years 
 later 
24-59 months      1 dose of 23PncPS  2 doses of PncCRM; 1 dose of 
  23PncPS  3-5 years later 
24-59 months      none   2 doses of PncCRM; 1 dose of 
  23PncPS 8 weeks after the last PncCRM; 
1 dose of 23PncPS 3-5 years later 
 
Reference [281] 
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Cost effectiveness Lieu et al [224] estimated that in the U.S. the 7-PncCRM vaccine would 
annually prevent more than 12,000 cases of pneumococcal meningitis and bacteremia, 53,000 
cases of pneumonia, 1 million episodes of AOM and 116 deaths. The vaccination of healthy 
infants would result in net savings for the society if the vaccine costs less than $ 46 per dose, 
and net savings for the health care payer if it costs less than $ 18 per dose. This cost-benefit 
calculation is conservative in terms of not considering the herd immunity effect, protection 
against cross-reacting serotypes and long term protection due to immunologic memory [38], 
but also optimistic for expecting reduction in the total number of AOM episodes, which, in 
light of the FinOM Vaccine study, may not occur [91, 177]. In Canada, the vaccination would 
results in net savings for the society if the vaccine costs less than $ 32 (Can$ 50) per dose 
[209]. In Finland, the vaccine is estimated to prevent at least 8000 cases of AOM, 1000 cases 
of pneumonia, and 60 cases of invasive diseases in infants [281]. The vaccination would 
results in net savings for the society if the costs would be less than $ 24 per dose (< 95.8 euros 
for 4 doses) [346].  
 
The availability and routine use of pneumococcal conjugate vaccines could have a very 
significant public health impact in developing countries [108, 222, 259, 284, 285]. However, 
the goal of ensuring global access to medicines of public health importance might be difficult 
to achieve for several reasons, of which the costs are the most critical. In 2001, the purchases 
of the licensed 7- PncCRM vaccine totalled over $700 million in the U.S. alone [420]. A dose 
of the vaccine currently costs $ 40 – 58 i. e. more than the combined price of all other vaccines 
in the EPI program in most developing countries. 
 
The licensure of pneumococcal vaccines  The licensure of new pneumococcal conjugate 
vaccines with sufficient serotype coverage (i. e. 9 – 11 serotypes) for global use has been 
difficult. The regulatory agencies, primarily the FDA and EMEA, have responsibility to their 
home markets, and the use of regulatory resources to evaluate products for different 
epidemiological situations is of low priority. Furthermore, the proposed licensure criteria of 
non-inferiority in immunogenicity when comparing the new vaccine candidates to the licensed 
7-PncCRM vaccine [446] may hinder the licensure of new conjugate vaccines world-wide 
[172]. Antibody responses to some PSs of the new vaccine may be higher or lower than for the 
licensed product. Dealing with this is statistically challenging [316]. Also, possibly due to 
genetic and other factors, the conjugate vaccines may elicit high responses in certain 
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populations making the comparisons of immunogenicity studies in different countries difficult 
[172]. Furthermore, the inferiority for rare serotypes might not be important in relation to the 
benefits of having additional vaccines licensed or potentially having additional antigens 
covered.  
 
Establishing serologic correlates of protection against pneumococccal diseases could fasten 
the development and licensure of new conjugate vaccines [172, 215]. If the future licensure is 
done based on immunogenicity and safety data, the comparison of rates of seroconversion to 
an agreed upon threshold may be preferable to the comparisons of GMCs between two 
vaccines [432]. The Kaiser Permanente study results suggest that induction of a minimal 
protective level of at least 0.2 µg/ml of IgG antibody may be a reasonable predictor of 
protective efficacy against IPD [215, 432]. If the protective response to vaccination is set to a 
certain threshold level, which would exceed the minimal protective level and thus be a more 
conservative estimate of protection, over 82% of study infants achieved a GMC > 0.5 µg/ml 
for all serotypes [215]. On the other hand, a study by Esposito et al [94] showed that antibody 
concentrations < 1.0 µg/ml were not protective against serologically diagnosed pneumococcal 
pneumonia. Also, the results from the FinOM Vaccine study suggest that at least for AOM, the 
protective antibody threshold may be different for each serotype [5, 91, 304]. Even low 
concentrations (0.5 µg/ml) predicted vaccine efficacy of 50% for the serotype 6B whereas 
GMCs of 2.0 µg/ml and > 10.0 µg/ml were required for the similar efficacy for 23F and 19F, 
respectively [162]. Furthermore, despite the differences in immunogenicity the efficacy of 
PncCRM and PncOMPC against vaccine-type pneumococcal AOM were similar [91, 177]. In 
addition to the certain quantity of antibodies achieved as response to vaccination, other factors 
such as persistence of antibodies, favourable isotype and IgG subclass distribution, 
demonstrated functional efficacy measured by standardised and validated OPA and induction 
of immunologic memory could also be considered as requirements for licensure [172, 215]
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AIMS OF THE STUDY 
 
The overall objective of this thesis was to evaluate the immunogenicity and safety of a new 
11-valent diphtheria toxoid and tetanus protein -conjugated pneumococcal polysaccharide 
vaccine (11-PncTD) in infants.  
 
The aims of the individual studies were to: 
 
1. Characterise vaccine type-specific polysaccharide IgG antibody responses following each 
vaccine dose (I) 
 
2. Describe the functional activity of antibodies (II)  
 
3. Describe the safety and tolerability of the vaccine (unpublished data) 
 
4. Describe vaccine type-specific polysaccharide IgG antibody responses to one and three -
dose schedules (III)  
 
5. Compare vaccine type-specific polysaccharide IgG antibody responses to the aluminium 
adjuvanted and non-adjuvanted vaccine formulations in Filipino, Finnish and Israeli 
infants (IV) 
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1. Study vaccine formulations 
 
The study vaccine (Aventis Pasteur, Lyon, France) included pneumococcal PS of serotypes 3, 
6B, 14 and 18C coupled to diphtheria toxoid and pneumococcal PS of serotypes 1, 4, 5, 7F, 
9V, 19F and 23F coupled to tetanus protein. It contained 1 µg/dose of PS type 1, 4, 5, 7F, 9V, 
19F and 23F, 3 µg/dose of PS type 3, 14 and 18C and 10µg/dose of type 6B. The vaccine was 
formulated either with an aluminium hydroxide adjuvant 300 ± 150 µg / dose, or without 
adjuvant.   
 
 
2. Vaccinees and Study design  
 
The data presented here arise from three separate studies. Two of the studies were conducted 
in the Philippines with the aluminium adjuvanted 11-PncTD vaccine formulation and one 
study in Finland and Israel with both the adjuvanted and non-adjuvanted vaccine formulations 
(Table 15). A written informed consent was obtained from the guardians of all study children. 
The study in the Philippines was approved by the Ethical and Institutional Review Board of 
the Research Institute for Tropical Medicine (RITM) in Manila. In Israel, the approval was 
given by the Ethics Committee of the Soroka University Medical Center and the National 
Ethics Committee in Jerusalem, and in Finland by the Ethics committee of the National Public 
Health Institute in Helsinki. 
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Table 15.  The main characteristics and design of the immunogenicity and safety studies   
Study code PNF06297 PNF10297 PNF31398 
Study design Randomised, 
controlled, double-
blinded for two 
vaccine formulations 
Open, uncontrolled Randomised, controlled, 
double-blinded for the 11-
PncTD and MenA/C 
vaccine groups, 
randomised, controlled, 
open for the control group 
with one 11-PncTD dose 
Adjuvant to 
11-PncTD 
 50 % with and 50% 
without an adjuvant 
Yes Yes 
Control 
vaccine 
No No Men A/C conjugate 
vaccine 
Study period 1998-99 1998-99 1999-2000 
Study are Kerava, Joensuu and 
Salo in Finland and 
Beer Sheva in Israel 
Cabuyao in Laguna, 
Luzon, the 
Philippines 
Bohol island in the 
Philippines 
Study subjects Healthy infants, 
N=251 in two groups  
Healthy infants, 
N=51 
Healthy infants, N=180 in 
three group of 60 each 
Vaccination 
schedule 
2, 4, 6 and 12 months 6, 10 and 14 weeks. 
9 months 
6, 10 and 14 weeks, 9 
months; for the control 
group only one dose of 11-
PncTD at 18 weeks of age 
Blood 
sampling 
schedule 
2, 7, 12 and 13 
months 
6, 10, 14 and 18 
weeks, 9 and 10 
months 
6 and 18 weeks, 9 months 
 
 
3. The concomitant vaccines 
 
In the Philippines, the infants received BCG by 2 weeks of age, diphtheria, tetanus, whole-cell 
pertussis and Haemophilus influenzae type b (DTwcP//PRP-T, Aventis Pasteur, France), oral 
polio vaccine (OPV, Aventis Pasteur, France) and plasma derived Hepatitis B (HBV, 
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MedTest, Korea) vaccines at 6, 10 and 14 weeks of age, as well as measles vaccine (Aventis 
Pasteur, France) at 9 months of age.  
 
In Israel, all infants received HBV vaccine (Aventis Pasteur, France) at 0, 1 and 7 months, 
diphtheria, tetanus, whole-cell pertussis, PRP-T and inactivated polio (DTwcP-IPV//PRP-T, 
Aventis Pasteur, France) at 2, 4, 6 and 12 months of age and OPV (Aventis Pasteur, France) at 
7 and 13 months of age. The measles vaccine was also given at 12 months of age. In Finland, 
the infants received BCG at birth and DTwcP-IPV//PRP-T vaccine (Aventis Pasteur, France) at 
2, 4 and 6 months of age. 
 
 
4. Measurement of humoral immune responses 
 
4. 1. IgG EIA determination 
 
A standard EIA method was used for the measurement of IgG anti-pneumococcal PS 
antibodies [173]. The step-wise description of the method included:  
1. Wells of microtiter plates (Maxisorp; Nunc, Roskilde, Denmark) were coated with 
the respective PSs (5 to 10 µg/ml, depending on the PS; ATCC, Rockville, MD) in 
pyrogen-free phosphate buffered saline (PBS) by incubating for 5 hours at 37°C, and 
blocked with 10 % fetal calf serum in PBS (F-PBS).  
2. Serum samples were diluted 1: 100 in F-PBS containing 10 µg/ml Pneumococcal-C 
polysaccharide absorbent (Statens Serum Institutet, Denmark). After 30 minutes of 
incubation with absorbent at room temperature 3-fold dilutions in F-PBS were 
transferred to microtiter plates by pipette and incubated at 37 C for 2 hours. 
3.  Alkaline phosphatase-conjugated anti-human IgG (Sigma Diagnostics, St. Louis, 
U.S.A) was diluted in F-PBS, added to the wells and incubated for 2 h at 37°C before 
adding of the substrate, p-nitrophenyl phosphatase (Sigma Diagnostics, St. Louis, 
U.S.A).  
4. The A405 was read on an EIA reader (Multiscan MCC/340; Labsystems, Helsinki, 
Finland). The results were given as micrograms per millilitre calculated on the basis of 
the assigned IgG values of the 89-SF2 reference serum.  
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5. The detection limits for each specific pneumococcal serotypes were: type 1 - 0.1, type 
3 - 0.07, type 4 - 0.07, type 5 - 0.15, type 6B - 0.09, type 7F - 0.08, type 9V - 0.08, type 
14 - 0.14, type 18 C - 0.07, type 19F - 0.17, type 23F - 0.09 µg / ml, respectively. 
Antibody concentrations under the EIA detection limit for each serotype were assigned 
an arbitrary value, half of the detection limit. 
 
 
4. 2. Opsonophagocytic assay 
 
The method for evaluating the killing of live pneumococci by cultured and differentiated HL-
60 cells (promyelotic leucemia cells; ATCC, Manassas, VA) in the presence of serum and 
complement was applied by Anttila et al. [18] from the technique originally described in 1997 
by Romaro-Steiner et al. [337]. The pneumococcal serotypes chosen for the OPA included the 
most immunogenic serotypes 4 and 19F, the least immunogenic 6B and 23F, and serotype 14, 
against which the vaccine response was poorest.  
 
The HL-60 cells were grown in RPMI-1640 medium (Life Technologies, Paisley, Scotland) 
containing 16% heat-inactivated FBS (Gibco BRL, Life Technologies, Germany), 1% L-
glutamine (Life Technologies), Penicillin and Streptomycin. The differentiation of HL-60 cells 
was carried out by adding 1.55 ml N, N-dimethylformamide (DMF; Sigma Chemicals, St 
Louis, MO) in 200ml of culture media containing 2x105 cells/ml. The cells were allowed to 
differentiate at 37°C in 5% CO2 atmosphere for 5 days prior to the assay. The differentiated 
HL-60 cells were used in the assay in effector cell: bacteria ratio of 400: 1. The differentiated 
cells were harvested by centrifugation and washed two times in Hank’s balanced salt solution 
without Ca2+, Mg 2+, or phenol red (Life Technologies)  -containing 0.2% Bovine serum 
albumin (BSA; Sigma). The cells were re-suspended in Hank’s solution and immediately used 
in the assay. 
 
All test and control serum samples were heat-inactivated. The duplicate dilutions of each 
serum sample were done in opsonophagocytosis buffer (Hank’s balanced salt solution with 
Ca2+, Mg 2+, and 0.1% gelatin) in the microtiter plates. The total volume of serum dilutions 
was 10 µl/well. After all serum samples were diluted, 20 µl of bacterial suspension, prepared 
by dilution from a frozen stock (CDC, Atlanta, GA) in opsonophagocytosis buffer, was added 
  54
MATERIALS AND METHODS 
 
into each well, and the plates were incubated for 15 minutes at 37° C in 5% CO2 atmosphere. 
After adding 10 µl of complement (Baby rabbit complement; Peel-Freez Biologicals) and 40 
µl of washed HL-60 cell suspension into each well, the plates were incubated for 45 minutes 
in 37°C with horizontal shaking (220 rpm). After the incubation, 5µl from each well was 
pipetted onto a solid medium plates (Todd-Hewitt Broth, with 0.5% yeast extract and 1% 
agar). Bacterial colonies were counted after overnight incubation of the plates in 37°C in 5% 
CO2 atmosphere.  
 
The OPA was expressed as a titer that is the reciprocal of the serum dilution yielding 50% 
killing compared with the bacterial growth in the complement controls with no serum. If no 
OPA was detected (OPA < 8), the serum was assigned a titer of 4. Due to the lack of 
sensitivity, the OPA may not have been detectable if the respective concentration of antibodies 
measured by EIA was lower than 1.0µg/ml. The reproducibility of the OPA assay was 
followed by including a positive control serum on each plate. Only variation of one dilution or 
less was accepted for the OPA titer of the control sera. 
 
 
5. Vaccine safety evaluation 
 
Each infant was observed for 30 minutes after the injection for any immediate vaccine related 
reactions. A digital thermometer was supplied to parents to measure infants’ rectal 
temperature. Local reactions such as induration, redness and swelling were measured by a 
plastic calliper.  Fever was defined as rectal temperature > 38oC whereas the local reactions 
were considered significant if measured > 2 cm. The parents or guardians were asked to record 
local and systemic reactions in the evening of the vaccination day (approximately 8 hours after 
injection) and in the morning of the first to fifth day post-vaccination. The safety surveillance 
data was then collected by study personnel and entered to the database. Important medical 
events, such as all hospital admissions, were followed up by study personnel and reported as 
serious adverse events. For the statistical analysis, the local and systemic reactions were 
classified using the severity scale mild, moderate and severe for each of the clinical signs and 
symptoms listed in Table 16. The relationship of the adverse event or the serious adverse event 
(SAE) to the study vaccine was established by the investigator, using the following scale: not 
related, possible, probable, and definite. 
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The vaccine safety profile evaluation included: 
1. The immediate reactogenicity (reactions within 30 minutes of each injection, with emphasis on 
allergic reaction) 
2. The solicited local and systemic reactogenicity measured from day 0 to day 5 after each dose. 
3. Any adverse event (solicited and unsolicited) resulting in a visit to a physician between each 
injection and the following visit for the primary immunisation and one month after the booster 
vaccination. 
4. Any serious adverse event (SAE) occurring from the inclusion throughout the study.  
 
Table 16.  The vaccine safety parameters 
 
Local reactions 
 
Mild Moderate Severe 
Induration, Redness, 
Swelling (Normal 0-
2cm) 
2cm - 4cm 4cm - 7cm >7cm 
Local pain React when site is touched 
Cries when site is 
touched 
Cries when site 
moved 
 
Systemic reactions 
 
Mild Moderate Severe 
Rectal temperature 38°C-38.7°C 38.7°C-40°C ≥ 40°C 
Vomiting >1 episode Vomiting after each feed 
Vomiting regardless 
of the feed 
Diarrhoea: at least 1 or 2 
stools more than usual, 
with unusual aspect 
Severity grading according to investigator’s judgement 
Crying 
 
More than usual 
but normal 
Unusually high 
pitched crying 
Persistent crying more 
than 3 hours 
Unusual drowsiness 
 Severity grading according to investigator’s judgement 
Irritability 
 
Irritable for less 
than one hour 
Irritable between 
1 and 1 hours 
Irritable for more than 
3 hours 
Anorexia 
 
Subject’s 
appetite is low 
Subject refuses 
from 1 to 2 feeds 
Subject refuses most 
of the feeds 
Insomnia 
 Severity grading according to investigator’s judgement 
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6. Statistical methods 
 
All statistical calculations were performed by using log-transformed data. The results (Study 
objectives I, II) are presented as geometric mean concentrations (GMCs) and geometric mean 
opsonophagocytic titers (GMOPA) with 95% confidence intervals, proportions of infants with 
over 2- and 4-fold increases between different series as well as reverse cumulative 
distributions (RCDs of antibodies). Statistical comparisons between GMCs at different time 
points in Filipino infants were done with a paired t-test with a set value of significance of P < 
0.05. The Spearman coefficient correlation test was used to analyse the correlation between 
antibody concentrations and respective OPA titers to the homologous serotype.  
 
The Fisher’s exact test was used for comparison of local reactions associated with EPI and 
study vaccine injection sites. Chi square test was used to analyse the rates of systemic 
reactions after each vaccine dose. 
 
The comparisons of antibody responses to one or three vaccine doses (Study objective III) 
were conducted by utilising a generalised linear model, in which each serotype expressed the 
antibody concentration as a function of the vaccine group at each time (a vaccine by time 
interaction). This was done within the SAS procedure GENMOD, which allows the estimation 
of parameter contrasts of interest. Because the log-transformed concentrations appeared to be 
normally distributed, the identity link function and the normal error distribution were used. 
Time was specified as a repeated factor. The statistical significance test results are reported 
using χ2 probability values. Paired t-tests were used to compare pre- and post- vaccination 
level at 18 weeks.  
 
The hypothesis of equal GMCs among Filipino, Finnish and Israeli infants at each time points 
and for both vaccine formulations was tested by using the analysis of variance (F-test) for each 
individual serotype (Study objective IV). Following the overall F-test showing significant 
differences in GMCs, a post hoc Dunnett's T3 pair-wise comparison test based on the 
studentised maximum modulus was used to determine a geometric mean ratio with 95% 
confidence interval for each compared GMC. A confidence interval of a ratio excluding one 
was termed significant. The Dunnett's test allowed multiple comparisons among GMCs with 
the overall error rate remaining below 5%.
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1. Vaccine immunogenicity 
 
The immunogenicity of the 11-PncTD vaccine in Filipino infants was evaluated in two 
separate studies. The first study (PNF10297) was an open, controlled study in which the main 
emphasis was to evaluate antibody responses to each of the four vaccine doses. The second 
study (PNF31398) compared pneumococcal antibodies in groups receiving either one or three 
doses of 11-PncTD vaccine, or three doses of MenA/C control vaccine. In the PNF10297 
study, 50 infants (23 girls, 27 boys) who met the inclusion criteria and had none of the 
exclusion criteria were enrolled into the study. Of these infants, 47 (94%) received three doses 
of study vaccine, and 45 (90%) received also the fourth dose. The mean ages of infants at each 
vaccination visit were 6.6 weeks (range: 6-8 weeks) at dose 1; 10 weeks (range: 10-13 weeks) 
at dose 2; 15.1 weeks (range: 14-18 weeks) at dose 3 and 19.5 weeks (range 18-23 weeks) on 
the fourth visit when the post third dose serum sample was collected. Serum sample was 
available from 49 infants before the vaccination, 47 after the three doses of vaccine and from 
45 before and after the fourth dose, equal to a 90 % study completion rate. 
 
Anti- pneumococcal PS antibodies before vaccination.  Individual antibody concentrations 
at 6 weeks of age ranged from values below the detection limits to 26.9 µg/ml for serotype 
19F (Figure 2). The highest GMCs were against serotypes 14 and 19F, 1.54 and 0.96 µg/ml, 
respectively (Table 17). Pre- vaccination OPA was measured only for the serotype 14. The 
geometric mean OPA titer (GMOPA) was 46.8 and 67% of serum samples contained 
antibodies with a measurable OPA titer. The correlation between the concentration of 
antibodies and respective OPA titer was 0.82. 
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 Table 17.  Geometric mean concentration (GMC, µg /ml) and 95 % confidence intervals (CI) of antibodies against pneumococcal PSs 
  included in the eleven-valent pneumococcal vaccine given at 6, 10 and 14 weeks, and at 9 of age. Serum sample withdrawn 
  4 weeks after each vaccine dose.           
              
                Pneumococcal serotype 
Age  
 1 3 4 5 6B 7F 9V 14 18C 19F 23F   
              
         
6 wk 0.48 0.39 0.27 0.53 0.33 0.80 0.53 1.54 0.38 0.96 0.49   
(n=49) (0.34-0.68) (0.29-0.52) (0.19-0.38) (0.37-0.75) (0.24-0.45) (0.58-1.10) (0.37-0.74) (0.99-2.39) (0.27-0.53) (0.64-1.45) (0.34-0.70)   
              
10 wk 1.59 1.99 1.33 2.28 0.20 0.99 0.41 0.89 0.41 1.01 0.32   
(n=49) (1.12-2.26) (1.61-2.47) (0.87-2.03) (1.65-3.16) (0.14-0.28) (0.73-1.34) (0.30-0.56) (0.59-1.33) (0.28-0.60) (0.71-1.43) (0.23-0.45)   
              
14 wk 12.72 5.54 14.22 12.34 0.33 4.89 2.49 1.29 2.66 4.62 0.86   
(n=47) (10.2-15.92) (4.37-7.02) (11.19-18.06) (10.07-15.11) (0.23-0.47) (3.60-6.65) (1.87-3.30) (0.91-1.83) (1.86-3.82) (3.40-6.27) (0.63-1.17)   
              
18 wk 15.23 4.87 23.41 12.49 1.12 8.87 7.69 2.18 4.50 16.11 3.89   
(n=47) (12.75-18.19) (3.91-6.08) (18.95-28.92) (10.77-14.48) (0.77-1.61) (6.82-11.53) (6.27-9.43) (1.65-2.87) (3.18-6.38) (12.81-20.24) (2.83-5.34)   
              
9 mo 2.99 0.76 5.10 2.80 0.46 2.64 1.55 0.58 0.39 5.72 1.45   
(n=45) (2.28-3.93) (0.62-0.94) (3.89-6.69) (2.20-3.56) (0.35-0.61) (2.02-3.45) (1.14-2.11) (0.41-0.82) (0.26-0.58) (4.26-7.67) (1.01-2.08)   
              
10 mo 14.46 3.59 30.15 11.80 2.02 17.79 7.98 1.65 1.86 33.43 8.22   
 (n=45)  (11.36-18.40)   (2.81-4.58) (23.82-38.17)     (8.96-15.55) (1.37-2.98)       (13.34-23.74) (6.14-10.38)       (1.07-2.56)   (1.25-2.78)       (25.62-43.62) (5.90-11.45)
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Antibody response to the first vaccine dose.  A significant increase (p< .001) in the GMC of 
antibodies was measured against serotypes 1, 3, 4, 5 already after the first vaccine dose (Table 
18). The increase in the GMC against 7F, 18C and 19F was not statistically significant. At the 
same time the GMC of antibodies against serotypes 6B, 14 and 23F decreased significantly (p 
<.001). The individual variation in the responses to the vaccination was higher with the less 
immunogenic serotype 6B than with the more immunogenic serotype 4 as well as for 
serotypes 14 and 19F, for which the antibody concentrations at 6 weeks of age were highest 
(Figure 2). 
 
Figure 2.  Kinetics of anti-pneumococcal antibody response to 11-PncTD vaccine fo 
r serotypes 4, 6B, 14 and 19F in Filipino infants  
 
 
Antibody response to the second vaccine dose.  The GMCs of antibodies were 
significantly higher (p< .001) against all serotypes, except for serotype 14 (p= .129) and 6B 
(p= .014). When comparing the GMCs at 6 and 14 weeks of age (i.e. before vaccination and 
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after two vaccine doses), the GMCs were significantly higher against serotypes 7F, 9V, 18C 
and 19F, in addition to the 1, 3, 4 and 5, which were significantly higher already at 10 weeks 
of age, i.e. after the first vaccine dose (Table 18).  
 
Table 18.  The geometric mean concentration (GMC, µg/ml) and opsonophagocytic titers 
 (GMOPA) with 95% confidence intervals, the proportions of infants (%) with 
 detectable OPA activity, and the EIA-OPA -ratio following three (18 weeks of 
 age) and four doses (10 months of age) of 11-PncTD 
 
GMOPA OPA % EIA-OPA ratio 
Serotype 
3 doses 
(18 weeks,N = 47) 
4 doses 
(10 months,N = 44)
3 doses 4 doses 3 doses 4 doses 
4 277 
(201-382) 
3051 
(2388-3897) 98 100 0.078 0.010 
6B 12.3 
(7.7-19.8) 
125 
(62-251) 43 75 0.054 0.009 
14 46.0 
(26.4-80.0) 
221 
(102-479) 81 78 0.035 0.004 
19F 119 
(79.7-179) 
588 
(424-818) 94 98 0.119 0.054 
23F 206 
(126-338) 
1368 
(893-2096) 91 98 0.016 0.006 
 
Vaccination was scheduled at 6, 10, and 14 weeks, and 9 months of age. The EIA-OPA –ratio 
expresses the serotype specific antibody concentration (µg/ml) required to kill 50% of pneumococci in 
OPA.  
 
Antibody response to the third vaccine dose. A significant increase in the GMC of antibodies 
against serotypes 4, 6B, 7F, 9V, 14, 18C, 19F and 23F was measured when comparing to the 
GMCs at 14 and 18 weeks of age (Table 17). The GMC of antibodies against serotype 3 
decreased, but not significantly (p =. 06). When comparing the GMCs at 6 weeks of age, i.e. 
before vaccination, and at 18 weeks of age, all GMCs, except against serotype 14 (p = .253) 
were significantly higher after three vaccine doses at 18 weeks of age. The percentage of study 
infants with 2 -fold increase in antibody concentration as response to three vaccine doses 
varied between 42.6 % for serotype 14 and 100 % for serotype 4. A 4 -fold increase was seen 
in 23.4 % of infants for serotype 14 and 95.7 % for serotype 4. At 18 weeks of age all infants 
had antibody concentration > 1.0 µg/ml against serotypes 1, 3, 4, 5, 6, 7F, 9V, 19F, whereas 
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49, 83, 91.5 and 87.2 % of infants had concentration > 1.0 µg/ml against serotypes 6B, 14, 
18C and 23F respectively. 
 
A high antibody concentration at 6 weeks of age correlated negatively with the response to the 
three vaccine doses for serotypes 4 (correlation coefficient -0.33, 95% CI –0.52; - 0.09) and 
23F (-0.35, 95% CL –0.55; - 0.11), but not for 14 (0.02, 95% CI –0.26; – 0.30) and 19F (-0.31 
95% CI –0.57; – 0.02), which had the highest pre-vaccination antibody concentration, or for 
any other serotype. 
 
After three vaccine doses most serum samples contained antibodies with measurable OPA. 
The proportion of samples with OPA ≥8 ranged from 43% for the serotype 6B to 98% for the 
serotype 4 (Table 18). Similarly to the antibody concentrations, the GMOPA was highest for 
the serotype 4 – titer: 276.9, and lowest for the serotype 6B - titer: 12.3. The correlation 
between the concentration of antibodies and the OPA titer varied from 0.53 for the serotype 
19F to 0.74 for the serotype 6B. The GMOPA: GMC –ratios were: serotype 4 – 11.8; type 6B 
– 10.7 ; type 14 – 21.1 ; type 19F – 7.4; and type 23F - 53.0.  
 
The persistence of antibodies from 18 weeks to 9 months.  The GMCs of antibodies against 
all studied serotypes were significantly lower at 9 months of age when compared to post third 
dose GMCs at 18 weeks of age (p < .005, Table 17). However, 8 infants (one for 6B, 7F, 9V, 
14, two for 19F, and 3 for serotype 23F) had at least a 2- fold rise in their anti-pneumococcal 
PS antibody concentration prior to the fourth dose at nine months of age, suggesting either 
asymptomatic carriage acquisition or symptomatic infection by the respective pneumococcal. 
 
Antibody response to the fourth vaccine dose  The fourth vaccine dose elicited 
significantly higher GMC of antibodies against all serotypes (p < .001, Table 17) when 
compared with the concentrations before the vaccine dose at 9 months of age. However, in 
comparison with the concentrations at 18 weeks of age, i.e. following the three vaccine doses, 
the GMCs of antibodies against serotypes 7F, 19F and 23F were significantly higher (p < 
.001), and of the serotype 18C were significantly lower (p =  .002). For serotypes 1, 4, 5, 7F, 
9V and 19F, 100 % of infants had antibody concentration > 1.0 µg/ml. For the remaining 
serotypes 3, 6B, 14, 18C and 23F, the percentages were 97.8, 73.3, 62.2, 71.1 and 97.8%, 
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respectively. Antibody concentration at 6 weeks of age had no significant correlation with the 
response to the fourth vaccine dose. 
 
After the fourth vaccine dose the GMOPAs were significantly higher for all studied serotypes 
(p < .001) when compared titers following the third dose. The OPA was measurable in 98% 
to100% of samples for serotypes 4, 19F and 23F, and in 75% and 78% of samples for 
serotypes 6B and 14, respectively. The correlation between antibody concentrations and OPA 
titers varied from 0.73 for the serotype 23F to 0.79 for the serotype 19F. The GMOPA: GMC 
ratio increased when compared to the post-third dose ratio, varying from 17.3 for the serotype 
19F to 163.2 for the serotype 23F (Table 18).  
 
 
2. Safety and tolerability  
 
The 11-PncTD vaccine was safe and well-tolerated. The most common local reactions in order 
of frequency were induration, pain, swelling and redness (Table 19). The rate of local 
reactions between the two injection sites, those associated with the study vaccine and the 
DTwP//PRP-T vaccine, were almost of equal frequency following each of the three doses, 
except for induration. The rate of induration was significantly higher for all of the three doses 
in the DTwP//PRP-T vaccine than the study vaccine site (Dose 1: 45.1 % vs. 7.8 %, p <0.001; 
dose 2: 30.6 % vs. 10.2 %, p <0.01; and dose 3: 19.1% vs. 4.3%, p<0.02).   
 
Table 19.  Local reactions (%) within the first 5 days after vaccination in infants 
   receiving three doses of DTwP//PRP-T, OPV, hepatitis B and the 11-PncTD vaccines 
 
    Dose 1                      Dose 2                             Dose 3 
Reaction              DTP         11-PncTD              DTP         11-PncTD            DTP     11-PncTD 
Local reactions  64.7         41.4        42.9     26.5   24.0      23.4 
Induration      45.1             7.8                 30.6             10.2               19.1          4.3 
Pain                   45.1           27.5                 30.6             22.4               23.4         21.3  
Redness              7.8              0                     2.0                 0                  2.1            0 
Swelling           16.0             8.0                    6.1               4.1                 0               0 
 
Local reactions >2cm. Vaccine administered at 6 (N = 50), 10 (N= 49) and 14 (N= 47) weeks of age  
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The clinical parameters included for the evaluation of systemic events after each dose included 
fever, vomiting, diarrhoea, inconsolable crying, unusual drowsiness, irritability, anorexia and 
insomnia (Table 20). The rates of fever (>38oC) after each of the three doses were 40.0%, 
22.3% and 21.3%. Fever of 38.7oC or more occurred at 8 %, 12.2% and 8.5% of the infants. 
All local and systemic events resolved without medical intervention. There was a trend in the 
frequency of both local and systemic reactions to decrease with successive doses of vaccine. 
 
Table 20. Systemic reactions (%) within the first 5 days after vaccination in infants 
 receiving three doses of DTwP//PRP-T, OPV, hepatitis B and the 11PncTD  vaccines 
 
Reaction                 Dose 1                 Dose 2                   Dose 3 
 
All systemic           80.4   53.1         46.8 
Fever            40.0                22.3                       21.3  
Vomiting 4.0  2.0  4.3 
Diarrhoea   10.0  6.2 10.6 
Inconsolable crying 34.0 28.6 14.9 
Unusual drowsiness 16.0  2.0  2.1 
Irritability 44.0 24.5 10.6 
Anorexia 14.0  8.2  6.4 
Insomnia 36.0 12.2 10.6 
 
Vaccine administered at 6 (N = 50), 10 (N= 49) and 14 (N= 47) weeks of age  
 
There were nine serious adverse events, which consisted of eight hospitalisations. The reasons 
included: one case of suspected meningitis, 2 cases of acute gastroenteritis, 3 cases of 
bronchopneumonia, one case of bronchitis and one urinary tract infection. The patient with 
suspected meningitis had received immunization 17 days before the onset of fever and 
convulsions, which led to death very soon after admission to hospital. The aetiology of 
infection remained unconfirmed. All these adverse events were reported as not related to the 
study vaccine by the investigators. There was one hypotensive hyporesponsive episode that 
occurred 20 minutes after administration of 11-PncTD and DTwP//PRP-T vaccines. The 
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episode resolved within 15 minutes and was considered probably study vaccine related. 
Another case of cyanosis of the lips and nails, fever and chills was reported the day of the third 
vaccination and was considered probably related to the vaccination by investigators. At 
follow-up, this event was re-evaluated as being non-serious. The investigator, however, 
decided to withdraw the subject from the study.  
 
 
3. Comparison of one and three doses vaccination schedules at 9 months of age  
 
In a separate immunogenicity and safety study conducted in Bohol, the Philippines 
(PNF31398), the antibody concentrations before and after three vaccine doses were similar to 
those reported earlier in the PNF10297 study, and significantly higher than in the group 
receiving the MenAC control vaccine. Surprisingly, the GMCs of antibodies at 9 months of 
age were similar in infants receiving one dose of 11-PncTD at 18 weeks of age as in those 
receiving the conventional three doses schedule at 6, 10 and 14 weeks of age. Statistically 
significant differences between these two groups were found only for serotypes 3 and 7F, in 
which the GMCs were higher in the group receiving just one dose (p<0.05), and for 9V where 
the GMC was lower in the one dose group (Table 21). The percentage of infants with antibody 
concentrations >1.0 µg/ml was not significantly different for the two groups for all serotypes, 
except for serotype 3 (p < 0.001) in which the percentage was higher for the one dose group. 
No significant differences were found for the percentage of antibody concentrations above 
0.15 µg/ml and 0.30 µg/ml between these two groups at 9 months of age.  
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 Table 21.  Geometric mean concentrations of antibodies for the 11 pneumococcal serotypes at 18 weeks and 9 months of age for children 
 given either 3 doses of 11PncTD vaccine, 1 dose of 11PncTD, or given only the control vaccine (MACV group) 
 
   Serotype and Geometric Mean Concentration, µg/ml  (95% CI) 
Age at the 
time of 
sample 
Doses Group (N)  1 
 
3 
 
4 
 
5 
 
6B 
 
7F 
 
9V 
 
14 
 
18C 
 
19F 
 
23F 
18 weeks 3 11PncTD3 N= 56 
11.22 
(9.43-13.36) 
4.98 
(4.20-5.91) 
18.40 
(14.99-22.59)
11.46 
(9.41-13.95) 
1.16 
(0.84-1.61) 
8.11 
(6.17-10.68) 
6.61 
(5.07-8.62) 
2.81 
(1.95-4.04) 
3.78 
(2.77-5.16 
16.06 
(11.54-22.34)
3.15 
(2.07-4.80) 
 1  
11PncTD1 
N=54 
0.12 
(0.10-0.15) 
0.13 
(0.10-0.16) 
0.10 
(0.08-0.12) 
0.17 
(0.13-0.21) 
0.11 
(0.09-0.14) 
0.13 
(0.10-0.17) 
0.13 
(0.10-0.16) 
0.28 
(0.21-0.36) 
0.07 
(0.06-0.09) 
0.31 
(0.25-0.40) 
0.13 
(0.10-0.17) 
 0 MACV N=56 
0.15 
(0.11-0.19) 
0.13 
(0.11-0.16) 
0.12 
(0.09-0.15) 
0.22 
(0.17-0.29) 
0.12 
(0.09-0.15) 
0.16 
(0.13-0.20) 
0.14 
(0.11-0.18) 
0.34 
(0.26-0.45) 
0.11 
(0.08-0.15) 
0.36 
(0.27-0.47) 
0.13 
(0.10-0.17) 
9 months 3  
11PncTD3 
N= 56 
2.06 
(1.66-2.56) 
 
0.68 
(0.55-0.84) 
3.92 
(3.04-5.05) 
2.67 
(2.13-3.35) 
0.53 
(0.41-0.70) 
 
2.65 
(2.16-3.25) 
1.30 
(0.99-1.71) 
1.02 
(0.74-1.40) 
0.32 
(0.25-0.41) 
5.01 
(3.80-6.60) 
1.00 
(0.70-1.44) 
 1  
11PncTD1 
N=54 
1.57 
(1.29-1.90) 
 
1.68 
(1.36-2.07) 
5.81 
(4.45-7.58) 
2.29 
(1.87-2.80) 
0.40 
(0.30-0.55) 
3.58 
(2.86-4.48) 
0.89 
(0.70-1.13) 
0.91 
(0.66-1.24) 
0.36 
(0.27-0.47) 
4.44 
(3.22-6.11) 
0.81 
(0.56-1.19) 
 0 MACV N=56 
0.10 
(0.08-0.13) 
0.23 
(0.15-0.34) 
0.11 
(0.08-0.15) 
0.28 
(0.21-0.36) 
0.11 
(0.09-0.14) 
0.16 
(0.11-0.22) 
0.11 
(0.08-0.14) 
0.21 
(0.16-0.27) 
0.07 
(0.06-0.09) 
 
0.25 
(0.19-0.33) 
0.10 
(0.07-0.13) 
 Three doses of 11PncTd were given at 6, 10 and 14 weeks of age. One dose of 11PncTd was given at 18 weeks of age. 
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4. Comparison of antibody responses in Filipino, Finnish and Israeli infants  
 
The immunogenicity results from the PNF10297 study were compared with the results of a 
multi-centre immunogenicity and safety study (PNF06297) conducted in Finland and Israel. 
The aim was to identify possible differences in antibody responses and discuss factors 
affecting the immunogenicity of the vaccine in different epidemiological settings.  
 
Pre- vaccination antibody concentrations.  The pre-vaccination antibody concentrations were 
determined for 49 Filipino, 118 Finnish and 123 Israeli infants. The pre-vaccination GMCs of 
antibodies were similar in Filipino and Israeli infants, but both had higher GMCs than the 
Finnish infants, significantly so against pneumococcal serotypes 1, 7F and 14 in Filipino, and 
against serotypes 6B, 9V, 14, 18C and 23F in Israeli infants (Figure 3).  
 
Figure 3 Pre-vaccination GMCs of anti pneumococcal PS antibodies in Finnish, Israeli 
 and Filipino infants 
1 3 4 5 6B 7F 9V 14 18C 19F 23F
GMC 
ug / ml
Pneumococcal 
serotypes
Pre-vaccination antibody concentrations
Finnish
Filipino
 
0,1
1
10
Israeli
Serum samples collected at 2 months of age in Finnish and Israeli infants, and at 6 weeks of age in 
Filipino infants. 
 
Antibody response to three doses of aluminium adjuvanted 11-PncTD vaccine. Three doses of 
the alum adjuvanted 11-PncDT elicited significant increase in anti-pneumococcal PS 
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antibodies against all eleven serotypes in all three populations (Figure 4). In Filipino infants, 
the GMCs for pneumococcal serotypes conjugated to diphtheria toxoid (types 3, 6B, 14 and 
18C) were 1.3 – 3.0 and 0.7 – 2.9 times higher than the GMCs in Finnish and Israeli infants, 
respectively. The GMCs for the serotypes conjugated to tetanus protein (types 1, 4, 5, 7F, 9V, 
19F and 23F) were 1.8 – 6.7 and 1.4 – 5.0 times higher in Filipino than in Finnish and Israeli 
infants, respectively.  
 
The Filipino infants generally responded to vaccination with higher antibody concentrations, 
and a higher proportion of infants achieved any given cut off concentration such as 0.15, 0.20, 
0.5 or 1.0 µg/ml of antibodies against all pneumococcal serotypes, apart from 6B and 14, 
against which the responses were similar in all three populations  
 
Figure 4.  The GMC of anti-pneumococcal antibodies after three doses of 11-PncT 
vaccine in Finnish, Israeli and Filipino infants 
 
1 3 4 5 6B 7F 9V 14 18C 19F 23F
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1
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vaccine doses
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Filipino
 
Israeli
The vaccine was scheduled to be given at 2, 4 and 6 months of age in Finnish and Israeli infants, and at 
6, 10 and 14 weeks of age in Filipino infants. Serum samples were collected one month after the third 
vaccine dose.   
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Antibody response to three doses of non-adjuvanted 11-PncTD vaccine   The non- 
adjuvanted vaccine formulation was given only to Finnish and Israeli infants. It was 
immunogenic, but the GMCs of antibodies were 0.58 – 0.95 and 0.52 – 0.78 times the 
respective GMCs received with the alum adjuvanted formulation in Finnish and Israeli infants, 
respectively.  
 
Antibody responses to the fourth dose of vaccine The data of the antibody responses before 
and after the fourth vaccine dose given at 9 months of age in Filipino infants and 12 months of 
age in Finnish and Israeli infants was available only in the groups receiving the alum 
adjuvanted formulation (Figure 5). The GMCs of antibodies decreased significantly prior to 
the fourth vaccine dose in all three populations. The GMCs for pneumococcal serotypes 
conjugated to tetanus protein, however, still remained higher in Filipino infants while there 
was no significant differences in serotypes conjugated to diphtheria toxoid.  
 
After the fourth vaccine dose the GMCs of antibodies were significantly higher than before the 
vaccination in all three populations. The GMCs for serotypes conjugated to diphtheria toxoid 
were of the same class of magnitude in Filipino, Finnish and Israeli infants. The GMCs for the 
types conjugated to tetanus protein were, however, 2.4 – 5.5 and 1.5 - 4.2 times higher in 
Filipino than in Finnish and Israeli infants, respectively. The Israeli infants generally had 
higher GMCs of antibodies than Finnish infants. Considering GMCs following three or four 
doses, the fourth vaccine dose increased the GMCs in the Finnish and Israeli infants, whereas 
the Filipino infants generally had similar GMCs as following the third dose.  
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Figure 5. Pre and post 4th 11-PncTD vaccine dose GMCs of anti-pneumococcal PS 
 antibodies in Finnish, Israeli and Filipino infants 
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The 4th vaccine dose was scheduled to be given at 12 months of age in Finnish and Israeli infants, and 
at 9 months of age in Filipino infants. The serum sample was collected one month after the vaccination.  
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DISCUSSION 
 
 
1. Study design and methodological aspects  
 
The studies presented in this thesis were conducted before the start of the vaccine 
effectiveness study in July 2000 in Bohol, the Philippines. The primary aim of these phase II 
studies was to ensure that the vaccine was safe and immunogenic, justifying further 
evaluation. These studies included only healthy children whose parents or guardians gave their 
consent to the study participation. Therefore, the safety and immunogenicity results as such 
should not be generalised to other populations, such as toddlers, adults or 
immunocompromised individuals.  
  
The laboratory methodology used to evaluate the immunogenicity of the vaccine consisted of 
the EIA and opsonophagocytosis methods. Despite some minor methodological differences the 
results of the standardised EIA method used at the KTL Vaccine immunology laboratory have 
been comparable with the results of different laboratories world-wide [316]. The main 
problem with the EIA method is the impurity of polysaccharide antigens. The CPS absorption 
improves the specificity of the assay [192], but the protein contaminants or cross-reactive 
epitopes on PSs may still show polyreactive antibodies without protective efficacy [271, 385]. 
A further removal of the polyreactive antibodies by inhibition with an irrelevant PS such as 
22F may improve the specificity of assay, especially for serum samples collected from adults 
or non-immunised individuals, but this is unlikely in post-immunisation samples from infants 
with low pre-existing antibodies [64].   
 
The opsonophagocytic assay for analysing the functionality of anti-pneumococcal antibodies 
has not been standardised to the extent of the EIA. The methodology used in different 
laboratories varies, which may reduce the reliability of inter-laboratory comparisons [432]. 
The results of the OPA may be affected by several factors. The use of live bacteria and HL-60 
cells is associated with certain biological variation, which can be monitored by including one 
or more control sera into each plate or assay. The HL-60 cells express only the FcγRII receptor 
allotype FcγRIIa-R131 of low affinity to IgG2 [336]. As infants respond mainly with IgG1 
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antibodies to pneumococcal vaccination, the possible FcγRII polymorphism of effector cells 
should not have affected the results. On the other hand, the varying expression of CR1 in 
different lots of HL-60 cells [338] could have increased the variability of results as the assay 
for the post-forth vaccine dose serum samples was performed several months after the post-
third dose samples analysis.  
   
Due to differences in methodology, the comparison of vaccine safety studies results is 
difficult. Many studies do not report the definitions used for different local and systemic 
adverse effects [139]. Also, the timing and conduct of recording the adverse reactions may 
have a significant impact on the results. The safety data presented in this thesis arise from the 
PNF10297 study, in which the study design was open. The parents and study staff could thus 
have associated more or less local adverse reactions to the study vaccine than the DTwP//PRP-
T vaccine, which was administered simultaneously, but to a different site. The safety of the 
vaccine was evaluated by using diary cards, which were filled by the parents during the five 
consecutive days following immunisation, and by nurses conducting home visits during the 
first and fifth day after the vaccination. Despite the careful translation, back translation and 
other standardisation methods, cultural and linguistic factors may have affected the rate and 
profile of adverse effects reported. However, the well-established study site with stabile 
population increased the likelihood that all serious side effects would have been detected by 
the study staff. 
 
The immunogenicity study conducted in Bohol was not initially planned to compare immune 
responses to one and three 11-PncTD vaccine doses. The immunogenicity results of the study 
conducted in Finland and Israel were also not planned to be compared directly to results 
arising from a different study in the Philippines. All serum samples were, however, analysed at 
the KTL laboratory by using the same standardised EIA methodology within a relatively short 
period of time. The statistical analysis of the results was conducted by using methodology, 
which decreased the probability of bias due to multiple comparisons. Furthermore, the 
possible bias was acknowledged by careful and conservative interpretation of the results.  
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2. Vaccine immunogenicity 
 
The 11-valent mixed carrier tetanus protein or diphtheria toxoid -conjugated pneumococcal 
vaccine elicited high concentration of functionally active antibodies in Filipino infants. The 
GMC of antibodies measured prior to vaccination at 6 weeks of age most likely reflected 
maternally derived antibodies [325]. The functionality of the pre-vaccination antibodies was 
measured only for serotype 14, for which the GMC was highest. The majority of the serum 
samples contained antibodies with measurable killing activity, which could provide in vivo 
protection against pneumococcal infections caused by type 14 during the first months of life. It 
is possible that the pre-vaccination antibodies against the other serotypes would also have had 
significant functional activity, but as the OPA method is currently not sensitive enough to 
determine functional activity of antibodies of low concentration this would have been difficult 
to determine. 
 
For some serotypes, such as 1, 3, 4 and 5, the GMCs of antibodies increased already after the 
first vaccine dose, whereas for the less immunogenic serotypes, such as 6B, 9V and 23F, the 
GMCs, actually decreased from 6 to 10 weeks of age reflecting the decrease of maternal 
antibodies. A similar variation in immunogenicity for different pneumococcal serotypes has 
been demonstrated in other studies [8, 12], although the majority of recent pneumococcal 
immunogenicity studies report only pre- and post-vaccination series GMCs for each serotype 
[440].  
 
Two vaccine doses elicited significant antibody responses against most pneumococcal 
serotypes, except for types 6B and 23F, which seemed to require three vaccine doses. If a 
certain cut-off GMC of antibodies, such as 0.2 µg/ml predicts protection against 
pneumococcal diseases, this suggests that at least a part of infants would be protected against 
infections caused by some of the serotypes included in the vaccine already after one or two 
doses of vaccine. This might be especially important in many developing countries, where 
many infants fail to receive the scheduled three or four doses of vaccines.  
 
After three vaccine doses the GMCs, except for serotype 14, were significantly higher than 
before vaccination. If the decline of maternally derived antibodies was taken into 
consideration the vaccine was immunogenic also for type 14. Most infants responded to 
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vaccination with at least 4 -fold increase in serotype specific antibody concentrations. The 
majority also reached antibody concentrations exceeding 1.0 µg/ml, and had antibodies with 
measurable functional activity. Antibody responses to each serotype varied considerably. The 
GMC of antibodies was highest for serotypes 4 and 19F, but neither of them had as high 
GMOPA: GMC -ratio as serotypes 23F or 14. Actually, the four-fold higher GMC of 
antibodies against serotype 19F compared to serotype 23F, resulted in lower killing activity in 
OPA.   
 
The problematic serotypes included 6B and 14. For type 6B, only half of the infants reached 
concentration 1.0 µg/ml and half of the serum samples did not have antibodies with 
measurable functional activity. However, due to the limited sensitivity of the OPA method to 
detect functional activity in low antibody concentrations, the negative OPA titers might not 
correlate with the lack of protection against pneumococcal disease. For type 14, the GMC of 
antibodies was relatively high already before vaccination, but the fold-increase in antibody 
concentration following three vaccine doses was modest.  
 
The GMC of antibodies for all eleven serotypes included in the vaccine decreased between the 
third and fourth vaccine dose, i. e. from 18 weeks to 9 months of age. The fourth vaccine dose 
elicited significant increase in the GMC of antibodies against all serotypes, but the GMCs 
were, in general similar to that achieved already with the first three vaccine doses. 
Contradictory to the GMCs, the functional activity of antibodies increased substantially after 
the fourth vaccine dose. This might be explained by the continuous maturation in the affinity 
of antibodies resulting in enhanced killing activity [18]. It is also possible that the serum 
samples following three vaccine doses included relatively more cross-reactive or non-
functional antibodies than following the fourth vaccine dose. The GMOPA titers for serotypes 
14 and 23F were similar to those reported from the study conducted in Finland and Israel with 
the same vaccine [438]. The major difference was that in Filipino infants the functional 
activity increased substantially after the fourth dose while the concentrations remained similar 
for most of the studied serotypes. In Finland and Israel both the concentration and 
functionality of antibodies increased after the fourth vaccine dose. Whether this finding 
indicates that four vaccine doses will provide significantly better protection against 
pneumococcal diseases can not be determined without evidence from an effectiveness study. 
When analysing individual responses, the high antibody concentrations or the OPA before 
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vaccination did not interfere with the subsequent quantitative or qualitative responses to the 
majority of the serotypes, including type 14. This suggests that the early EPI vaccination 
schedule, common in developing countries, with high burden of infectious diseases at early 
age does not lead to a compromised response to the pneumococcal conjugate vaccine.  
 
 
3. Safety and tolerability 
 
The safety data presented here arises from a relatively small safety and immunogenicity study. 
The results indicate that the 11-PncTD vaccine is safe and well-tolerated in Filipino infants. 
Local reactions such as redness, swelling, induration and pain at the site of the study vaccine 
injection were reported in 23-41% of infants. In general, and despite the possible 
methodological differences in safety evaluations, the other studies with the same or other 
pneumococcal vaccine candidates have reported similar rates of local reactions [39, 79, 91, 
410, 439, 440]. As observed in this study, the rate of local reactions has been substantially 
lower at the pneumococcal than at the DTP-Hib vaccine site [79, 440]. In studies conducted in 
Finland and Israel the aluminium adjuvanted 11-PncTD vaccine caused more local side effects 
when given to infants and toddlers, but less when given to adult than the non-adjuvanted 
formulation [79, 439, 442]. 
 
Fever was the most commonly noted systemic adverse effect following immunization. The 
rate, which varied between 10% and 20% depending on the number of doses, is similar or 
lower than in other studies, where fever above 38.5 C has been reported in up to 52% of 
children, 22 % of toddlers and 4% of adults [440]. In this study, the occurrence of fever 
decreased from 40% to 21% in infants, while in Finland and Israel it increased from 33% to 
53% with subsequent vaccine doses [80]. The reasons for this remain unclear.  
 
 There was one hypotensive hyporesponsive episode noted in this study, but whether it was 
due to 11-PncTD vaccine or other concomitantly administered vaccines is difficult to 
determine. Dagan et al [80] reported a rate of 0.8% to 6.4% for immediate (within 30 minutes 
from vaccination) adverse reaction with the same vaccine in Finnish and Israeli infants. 
However, none of the studies with the same or other pneumococcal conjugate vaccines have 
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reported serious concerns regarding the safety of pneumococcal conjugate vaccines [39, 91, 
410, 440].  
 
 
4. Different vaccination schedules 
 
The infants enrolled in the immunogenicity study (PNF31398) conducted in Bohol received 
either three doses of 11-PncTD at 6, 10 and 14 weeks of age, three doses of Men A/C control 
vaccine, or one dose of 11-PncTD at 18 weeks of age. The GMCs of antibodies before 
vaccination at 6 weeks of age were similar in all three groups, and remained low for the 9 
months follow up period in the MenA/C control group. While three doses of 11-PncTD 
vaccine elicited a high concentration of antibodies, similarly to the PNF10297 study, the 
surprising finding was that at 9 months of age the GMCs against most studied serotypes were 
similar in groups that had received one or three doses of 11-PncTD. The same finding was also 
reported by Lagos et al [201] in Chilean infants with the non-adjuvanted vaccine formulation. 
 
The study design did not include sampling one month after the vaccination in the group 
receiving one 11-PncTD dose. Therefore, the peak antibody concentration achieved with one 
vaccine dose at 18 weeks of age remains unknown. The most plausible reason for the good 
persistence of antibodies despite the lesser number of doses is carrier priming due to 
diphtheria toxoid and tetanus proteins. The infants had received 3 doses of DTwcP in their EPI 
schedule before the 11PncTD vaccination. Studies have shown that immunity to carrier 
proteins enhances the immune response to polysaccharides in subsequent immunizations with 
conjugate vaccines [118, 199, 310, 373]. This study suggests that similar priming may also 
occur for diphtheria toxoid-conjugated vaccines. The priming might also take place in utero 
due to maternal immunization with tetanus toxoid [118, 223, 274]. Another factor that could 
have facilitated the persistence of relatively high GMC of antibodies at 9 months of age is the 
nasopharyngeal carriage acquisition. The contacts with pneumococci may have acted as a 
natural booster, eliciting antibody responses between the last dose of vaccine at 14 weeks or 
18 weeks and the serum sample collection at 9 months of age.  
 
The clinical significance of the good persistence of pneumococcal antibodies already after one 
vaccine dose remains unclear. The functional activity of antibodies increased after the children 
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received the fourth vaccine. It is thus possible that the quantity of antibodies after one or three 
doses of vaccine might be similar, but the quality of antibodies differs in favour of more doses. 
If less doses would provide equal protection, the less expensive 1-dose or a 2-dose schedule of 
conjugate vaccines could greatly benefit countries currently considering whether the economic 
burden of pneumococcal diseases outweighs the cost of vaccination. 
 
 
5. Vaccine immunogenicity in different populations 
 
The GMCs of antibodies following three or four doses of 11-PncTD vaccine against 
pneumococcal serotypes, especially those conjugated to tetanus protein, were substantially 
higher in Filipino infants than in infants receiving other pneumococcal conjugate vaccines in 
other populations [7-8, 91, 151, 173, 207, 241, 246, 283, 287, 372], or in Finnish and Israeli 
infants [80], Icelandic infants [444], Chilean infants [201] or in Finnish toddlers [439] 
receiving the same vaccine.  
 
The pre-vaccination GMCs of antibodies were higher against several pneumococcal serotypes 
in Israeli and Filipino infants compared to Finnish infants. As these pre-vaccination antibodies 
are likely to be of maternal origin with a relatively short half -life, the difference could be 
explained either by the higher concentration of antibodies in pregnant women in the 
Philippines and Israel or by the earlier sample collection in Filipino infants. It is, however, 
unlikely that the slightly higher pre-vaccination concentration of antibodies observed in this 
study would explain the considerably higher antibody responses to three doses of 11-PncDT 
vaccine in Filipino infants. 
 
The antibody concentrations decreased before, and increased after the fourth vaccine dose. 
The GMCs of antibodies after the fourth vaccine dose were higher than after the third dose in 
Finnish and Israeli infants, but not in Filipino infants who generally reached GMCs similar to 
those following the third dose. The non- adjuvanted vaccine formulation, which was not tested 
in the Philippines, was immunogenic, but the GMCs of antibodies were lower than the 
respective GMCs achieved with the alum adjuvanted formulation. This difference was, 
however, within the pre-set criteria for non-inferiority. The non-adjuvanted formulation had 
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fewer local side effects [80, 201], and it was therefore chosen for the currently on-going 
effectiveness study in the Philippines.  
 
In general, comparisons of immune responses in different populations should be interpreted 
with caution as the study settings differ considerably. Priming, which could have explained the 
good persistence of antibodies at 9 month of age with just one dose of 11-PncTD given at 18 
weeks of age, could also be an important factor in explaining the high antibody concentrations 
in Filipino infants. Nearly 80% of the Filipino mothers of the infants participating in the study 
had received at least 2 doses of tetanus toxoid during the pregnancy, but none of the Finnish or 
Israeli mothers. This may have contributed to the high GMCs of antibodies against the 
pneumococcal serotypes 1, 4, 5, 7F, 9V, 19F and 23F, which are conjugated to tetanus protein. 
However, this is unlikely to be the single explanatory factor for the high GMCs of antibodies 
as responses against the diphtheria toxoid-conjugates of PS from pneumococcal serotypes 3 
and 18C were also significantly higher in Filipino infants than in Finnish or Israeli infants.  
 
It is also possible that an early contact with pneumococci, more frequent in the Philippines 
[77, 277, 396], led to higher antibody responses due to early priming and memory response 
achieved by one or more doses of pneumococcal conjugate vaccine.  
 
The immunogenicity of vaccines can vary across ethnic groups and correlate with specific 
genotypes. Greenberg et al. [125] reported that white and African-American infants had 
antibody levels 40% lower than Hispanic infants and 60% lower than Asian infants following 
three doses of tetanus protein conjugated Hib vaccine (PRP-T). Genetic factors may also 
explain higher responses to PRP-T vaccine in Chilean infants compared to Turkish and 
Belgian infants [147, 148] or in Venezuelan infants compared to U.S. infants [56], and lower 
responses to another Hib conjugate vaccine (PRP-OMPC) in Gambian infants compared with 
European or U.S. infants [54].   
 
The experience with pneumococcal vaccines is limited. Although the sample size (N = 30 per 
group) may have been too small, Miernyk et al  [246] did not notice clear differences in 
antibody responses to a 7-PncCRM vaccine in Alaskan native, Apache and Navajo Indian, and 
non-native, but ethnically heterogeneous American infants. On the other hand, the 7-valent 
PncCRM vaccine elicited somewhat higher antibodies in the Gambia [287] and as a 9-valent 
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formulation in South Africa [151, 241] than in Finland or in the U.S. [91, 368]. Also, the non-
adjuvanted 11-PncTD vaccine elicited higher antibody responses in Chilean infants compared 
to Finnish, Israeli and Icelandic infants [201, 444]. The problem with all these studies is that 
the study settings differ so much that the role of genetic factors is very difficult to distinguish 
from other factors possibly affecting the immunogenicity [268]. 
 
Although the Filipino infants received DTwcP//PRP-T while the Finnish and Israeli infants 
received DTwcP-IPV//PRP-T vaccine, it is unlikely that this or any other difference in the 
schedule of the concomitant vaccines could explain the considerable differences in the 
response to the 11-PncTD. The Filipino infants were younger than Finnish and Israeli infants 
when starting their immunisation program. The interval between vaccine doses was also 
shorter, i.e. 4 weeks in the Philippines and 8 weeks in Finland and Israel. In contrast to some 
earlier Hib conjugate vaccine studies, which suggest that a delay in the immunisation schedule 
results in higher antibody responses [198], this study and an earlier immunogenicity study [55] 
with three different Hib conjugate vaccines (PRP-T, HbOC and PRP-OMP) demonstrate high 
responses already at an early age in Filipino infants.  
 
 
6. Future considerations 
 
Immunogenicity and safety studies, both those presented in this thesis and those conducted in 
other populations, confirm that the new 11-PncTd vaccine is safe, well-tolerated and 
immunogenic. The next step in the development of this vaccine is to prove that the vaccine is 
effective in reducing pneumococcal diseases. Even if proven effective, the licensure of the 
vaccine is currently uncertain, as the vaccine might not meet the current non-inferiority criteria 
imposed by the FDA for new pneumococcal vaccine candidates. Although the antibody 
responses in studies conducted in the Philippines, Finland, Israel, Chile and Iceland have been 
satisfactory, these studies have been conducted with concomitantly administered whole-cell 
pertussis vaccine, which is known to booster antibody responses to conjugate vaccines. In the 
context of concomitantly given acellular pertussis vaccine, which is used in new combination 
vaccines in many industrialised countries, the antibody responses to the non-adjuvanted 
formulation of the 11-PncTD vaccine have been significantly lower [81]. Most countries in the 
world are still using the whole-cell pertussis vaccine, but as the main marketing areas for new 
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vaccines would probably include the U.S. and EU countries, the manufacturer of the 11-
PncTD vaccine, Aventis Pasteur, has decided, with the exception of the on-going effectiveness 
study in the Philippines, to stop the clinical development program for the vaccine. If the study 
in the Philippines demonstrates that the vaccine is able to reduce childhood pneumonia, it 
might still be possible that the licensure process could be continued either by Aventis Pasteur, 
or by other public or private parties with an interest in reducing the pneumococcal disease 
burden in developing countries.  
 
Parallel to the development of 11-PncTD vaccine, the licensed 7-PncCRM vaccine is gaining 
wide-scale use in many industrialized countries [420]. It is possibly soon licensed also as 9- 
valent formulation more suitable for global use. The post-licensure surveillance is, however, 
essential in order to estimate the extend of additional benefits such as herd immunity effect. 
The surveillance may also detect possible negative effects such as replacement of 
pneumococcal serotypes included in the vaccine with other serotypes, against which the 
vaccine would not be effective.  
 
The Global Alliance for Vaccines and Immunization (GAVI) has identified several key 
factors, which could facilitate the introduction of new pneumococcal vaccines in developing 
countries (Table 22) [420]. In 2000, GAVI sponsored a meeting between academia, vaccine 
industry, non-governmental organisations and various funding parties. The agreement known 
as the Accelerated Development and Introduction Plan (ADIP) targets ensuring an adequate 
supply of pneumococcal conjugate vaccines in developing countries by 2006.   
 
From the vaccine manufacturers point of view, the development of new pneumococcal 
conjugate vaccines may in the future require private-public partnerships, which address the 
non-profitability issues related to vaccine markets in developing countries [433, 433]. Also, 
the pneumococcal conjugates are likely to be developed in a variety of formulations and 
presentations either as stand-alone products or in combination with Hib or meningococcal 
vaccines [446].  
 
The next new type of pneumococcal vaccines to advance to the phase II and III clinical trials 
will probably be the protein vaccines. These vaccines offer possible benefits such as unlimited 
serotype coverage, but at the same time the whole concept of these vaccines is far less studied 
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than the Hib and pneumococcal conjugate vaccines. Several of the problems now hindering 
the global introduction of pneumococcal conjugate vaccines, such as licensure requirements, 
pricing and uncertainty in the country specific disease burden are also likely to apply to the 
protein vaccines. Nevertheless, the development of existing and new vaccines against the 
pneumococcal disease burden will ensure an abundant need for future research efforts. 
  
Table 22.  GAVI high priority areas in facilitating introduction of pneumococcal 
             conjugate vaccines in developing countries 
 
1. Develop methods to assess important disease burden measures in different settings 
2. Standardise chest radiographic diagnose of pneumonia 
3. Expand surveillance for laboratory confirmed pneumococcal disease 
4. Measure the pneumonia burden 
5. Establish long-term surveillance to evaluate the effect of vaccination 
6. Generate local advocacy and ownership from research efforts 
7. Find regulatory approaches for vaccines manufactured in the U.S. or Europe that are 
designed for use in developing countries 
 
Reference [420] 
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